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Abstract 
Chronic diseases are rising in incidence and prevalence because of the increase in life expectancy in 
many parts of the world and the advances in medicine that manage disease progression, rather than 
curing and alleviating the causes. Cataract is one such chronic condition. Identifying a therapeutic 
intervention that is successful in reversing or preventing cataracts may have applications for other 
chronic diseases of protein misfolding, such as diabetes and Alzheimer's disease as these have similar 
causation factors, notably oxidative stress and/or glycation. To date, surgery remains the only 
effective treatment for cataract and the search for alternatives is still ongoing. Cerium oxide 
nanoparticles (nanoceria) which have antioxidant, radioprotective and enzyme-mimetic properties 
have the potential to lead to an effective non-surgical treatment. However, nanoceria stability in 
physiological media is poor thus hindering their effective use in biomedical applications. In the work 
described in this thesis, a highly efficient one-pot synthesis of nanoceria (2–5 nm) has been achieved. 
The nanoparticles were coated with a novel hybrid coating (ethylene glycol, ethylene glycol mono- 
and di- acetates) providing the formulation with superior colloidal stability in physiological media. 
The ethylene glycol coated nanoceria formulation (EGCNPs), up to concentrations of 200 μg/ml, is 
not toxic to human lens epithelial cells and has no adverse effect on the cellular morphology, 
proliferation rate, mitochondrial morphology, mitochondrial membrane potential, ATP level, DNA 
integrity and basal reactive oxygen species (ROS) level. Exceeding the safe concentration of 
nanoceria leads to genotoxicity and apoptotic cell death mediated by ROS elevation and 
mitochondrial damage, a mechanism which is comprehensively investigated for the first time in 
human lens epithelial cells (HLECs). EGCNPs uptake in HLECs was found to be endocytosis-
dependent and the nanoparticles localised extensively in the mitochondria. This localisation has 
enabled the nanoparticles to protect HLECs against oxidative stress, act as a catalase mimetic and 
increase reduced glutathione/oxidised glutathione ratio (GSH/GSSG). Furthermore, it is shown for 
the first time that these nanoparticles can protect lens proteins against glucose-induced glycation that 
is a major cause of cataract particularly in diabetics. Together, these results demonstrate great 
potential for nanoceria in protecting against cataract and should be taken to in-vivo studies.
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1 Introduction 
1.1 The human lens: structure and physiology  
The human lens is positioned in the anterior segment of the eye behind the cornea and the 
iris (Figure 1-1). It is a biconvex structure within a semi-elastic basement membrane, the 
capsule to which are attached suspensory ligaments, collectively called the zonule that hold 
the lens in place and mediate the forces of shape change.1 The main function of the eye lens 
is to refract image-forming light  to the retina which transmits this information to the higher 
visual processes.2 The ability of the lens to carry out its function requires transparency which 
can be ascribed to the organisation of its proteins, the crystallins.3,4 The crystallins are 
contained within long fibre cells arranged in layers. When these cells differentiate their 
nuclei and endoplasmic reticulum become pyknotic (i.e. irreversible condensation of 
chromatin in the nucleus) and move to the equatorial region away from the optics axis to 
prevent light scattering.3,4 
 
Figure 1-1 Cross section of the human eye.5 
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The human lens is a unique organ that continually grows over the lifetime of the individual 
by laying down new layers of fibres over existing cells without shedding any tissue.6 It 
weighs approximately 65 mg at birth, 160 mg at the age of 10 and continues to grow to about 
250 mg by the age of 90.2,7  Its composition can be dissected into three main parts: the 
epithelium, the cortex and the nucleus all of which are enveloped in a capsular membrane 
(Figure 1-2).1,2 The function of each part is summarised in the following section: 
 
Figure 1-2 Cross section of the human lens.2 
 
1.1.1 Lens capsule 
The capsule is a collagenous base membrane that encases the lens structure and mediates 
forces from the ciliary muscle allowing the lens to alter its shape in the first four to five 
decades of life before it hardens and the lens loses accommodation for near and far vision.8 
In humans, it is first detected at 5-6 weeks from pregnancy.2 The elasticity of the capsular 
membrane plays an important role in the ability of the lens to change its shape, a process 
called accommodation to allow clear focus for near and far vision.9 Furthermore, the capsule 
acts as a diffusion barrier blocking the passage of infectious materials while maintaining 
healthy supply of essential nutrients such as glucose, amino acids and vitamin C.1,10   
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1.1.2 Lens epithelium 
The human lens epithelium is a monolayer of cuboidal cells located at the anterior part of 
the lens just below the lens capsule.11 These cells are responsible for the majority of the 
metabolic activity of the lens including differentiation into the lens fibre cells that form the 
bulk of the lens.11 The lens epithelium plays an important role in regulating the flow of 
nutrients, ions and antioxidants by virtue of having water channels (aquaporins) and 
sodium/potassium ATPase pumps within its structure.1 Three different aquaporins AQP0, 
AQP1 and AQP5 are expressed in different regions of the ocular lens maintaining a 
microcirculation inside the lens.1 Additionally, the lens epithelium actively synthesises 
important defence systems such as glutathione and ultraviolet filters (e.g. tryptophan 
derivatives protecting the lens from UV induced damage) which are transported into the lens 
cortex and nucleus protecting the lens against oxidative and radiative damage.12 As such, 
The lens allows efficient light transmittance with wavelengths up to 1200 nm with very little 
transmittances for wavelengths below 390 nm.2 The lens epithelial cells, contrary to their 
differentiated fibrous form in the cortex and nucleus, are rich with organelles and 
cytoskeletal proteins such as actin, α-actinin, myosin, microtubules, spectrin and vimentin 
which play their roles by maintaining the lens homeostasis and stabilising cell structure 
during vision accommodation respectively.13 The presence of tight junctions in the lens 
epithelium allows exchange of low molecular weight metabolites and ions.2 
1.1.3 Lens cortex and nucleus 
The lens epithelial cells differentiate into elongated fibre cells that are arranged in concentric 
layers to form the cortex and nucleus of the lens. There is no clear distinction between the 
cortex and nucleus as they have similar structure. These fibrous cells are predominantly 
made of crystallins proteins with increasing distribution towards the innermost part of the 
cortex creating a refractive index gradient. Therefore, the refractive index of the human lens 
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increases from 1.38 (73-80% water) in the cortex to 1.42 (68% water) in the nucleus.2 These 
proteins are mainly made of the crystallins protein family α-, - and λ- crystallins.14–18 The 
lens nucleus refer to the innermost part of the lens and its structure is similar to that of the 
cortex besides the fact that the cells are more tightly packed due to the accrual of cells 
overtime.19 The very limited extracellular space between the fibre cells is critical for 
maintaining the lens transparency.2 Due to the lack of protein turnover or recycling in the 
lens, the its continuous growth and the formation of new cellular layers pushing the old 
layers inwards, the lens nucleus contains the oldest proteins in the body that exist at birth.20 
1.2 Lens development and homeostasis 
The human lens epithelial cells are the metabolically active cells in the lens.11 Some of these 
cells differentiate into elongated fibre cells and move towards the lens equator.1,2,11 The 
elongation into fibre cells can be quite significant reaching up to 1000 times in length 
compared to the lens epithelial cells.21 In the lens epithelium, the majority of the lens 
crystallins are synthesised. The differentiated fibre cells are formed on top of each other in 
concentric layers with a rate of one cellular layer per day where older layers are pushed 
towards the cortex and nucleus.21 This growth pattern of the layers creates a protein gradient 
where the oldest proteins are found in the nucleus and the newly synthesised ones are present 
in the epithelium.21 
The absence of blood supply in the lens is compensated for by the presence of the aqueous 
humour in which the lens is bathed.22 The aqueous humour acts as a source of nutrients and 
antioxidants needed for the lens, in addition to a means of disposal of metabolites such as 
lactic acid.1,22 The in and out movement of nutrients and metabolites is regulated by water 
and ion channels which are positioned in both the lens epithelium and the cortex.23 The 
aqueous humour is rich with antioxidants (e.g. ascorbic acid) which are trafficked into the 
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lens through molecular transporters. In the lens epithelium, glutathione (GSH), a major 
lenticular antioxidant, is synthesised and subsequently transported into the nucleus through 
gap junctions.24 Contrary to GSH, ascorbic acid cannot be biosynthesised and has to be 
supplied exogenously.25 These antioxidants are essential in providing the lens with 
protection against oxidative damage throughout life by deactivating reactive oxygen species 
(ROS).26 This in turn provides the lens proteins with the necessary protection against post-
translational modifications (PTMs) such as glycation and oxidation maintaining the lens 
transparency.26 
1.3  Aetiology of cataract: a human lens disorder 
Cataract can be defined as the loss of the eye lens transparency causing opacification and 
resulting in the inability of the lens to properly focus light on the retina leading to blurred 
vision or complete blindness.21,22,26,27 Cataracts represent approximately half of the blindness 
cases worldwide with populations over 60 mainly affected.28,29 Although many factors have 
been associated with cataract, it is predominantly an age-related disorder where aging 
represents the major risk factor for its development.26 This is commonly referred to as senile 
cataract. Cataract can also be less commonly caused by other factors such  trauma, infections, 
or as a congenital disorder.29–31 Cataract can be subcategorised into three main types based 
on where the opacity develops. These are cortical, nuclear and posterior subcapsular 
cataracts.32 Subcapsular cataract presents the first signs of opacity under the lens capsule and 
have been associated with certain medications such as corticosteroids.29 Cortical cataract 
develops in the lens cortex and is linked to diabetes.29 Finally, nuclear cataract is the most 
common type of cataracts which develops in the lens nucleus and is strongly associated with 
age, hence its commonly referred to as age-related nuclear cataract (ARNC).26 
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The loss of the lens transparency is thought to be caused by the aggregation of crystallins as 
the lens ages and this may be linked to a progressive loss of solubility of lens proteins.22,26,33–
35 The formed aggregates in turn are thought to absorb and/or scatter light preventing it from 
being focused on the retina.33 Aggregation of the lens proteins can be induced by a number 
of post-translational modifications such as glycation, oxidation, deamination, truncation, 
phosphorylation, racemisation and crosslinking.1,22,26,33 These changes occur very slowly 
over decades and affect different layers of the lens. Additionally, with ageing, the chaperone 
activity of α-crystallin decreases making the other structural proteins more susceptible to 
aggregation.35,36 α-crystallin is a known molecular chaperone with structural similarity to 
small heat shock proteins (sHsps) which inhibits protein aggregation by binding to 
intermediates that are generated during cellular stress or protein translational in-vivo.37 
Several studies have demonstrated that α-crystallin can prevent thermal aggregation of the 
lens proteins and enzymes.35 Therefore, chaperones are deemed important for the control of 
the growth of human lens epithelial cells by preventing aggregation of key proteins during 
cell differentiation.37  
Oxidative stress is believed to be one of the major causes for protein modifications and 
inactivation in the human lens.38 For example, crystallins can undergo truncation at C- and 
N- terminal which leads to pronounced effect on solubility and stability.20 Many amino acids 
are also more prone to oxidation particularly tryptophan, cysteine and methionine. Oxidation 
of cysteine residues is particularly common in early stage cataract with more than 90% 
residues oxidised in late stages of progression.20 Oxidation of proteins can also lead to the 
formation of disulphide insoluble species.20 In the mitochondria, four electron reduction of 
oxygen (O2) into water (H2O) takes place to generate the necessary cellular energy in the 
form of ATP molecules, a process known as the electron transport chain.21 When oxygen is 
partially reduced, various reactive oxygen intermediates are generated which are commonly 
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known as reactive oxygen species (ROS).38 These include superoxide (O2
-), hydroxyl 
radicals (•OH) and hydrogen peroxides (H2O2).
38 ROS can also be introduced from 
exogenous sources such as smoking, ionising radiation, diet and air pollutants.21 In particular, 
UV exposure is commonly thought to be one of cataract inducers especially after middle age 
because of its ability to induce oxidative stress.39 The lens possesses natural UV filters such 
as the tryptophan derivatives, that with age, can be altered, lose their function, and 
potentially act as photosensitisers (i.e. an intrinsic source of ROS).13 Another common 
source of oxidative stress is diabetes, which accounts for 10-12% of extracted cataracts, 
where there is strong association between hyperglycaemia and ROS generation.40 Therefore, 
sugars are frequently used experimentally to induce cataracts in-vivo and ex-vivo.41,42 
Under normal physiological conditions, the generated ROS are deactivated by the 
antioxidant defence systems present in the lens. The defence systems in the lens can be 
enzymatic or non-enzymatic.29 Enzymatic antioxidants in the lens involve superoxide 
dismutase (SOD) that deactivates superoxide radicals, and catalases and peroxidases that 
break down hydrogen peroxide.38 On the other hand, non-enzymatic antioxidants 
mechanisms include the presence of GSH and ascorbic acid.43 The presence of these 
mechanisms ultimately protects the proteins from oxidative stress-induced protein damage.43 
In ARNC, however, these defence mechanisms weaken, and ROS generation exceeds the 
lens ability to neutralise them.21,22,26 ROS can then slowly damage the protein structure in 
the lens, and because of the lack of protein turnover, the damaged crystallins proteins will 
accumulate and aggregate over time causing the lens to lose its transparency.21,22,26  One 
prominent example of the weakened antioxidant system and its association with cataract 
development is the loss of GSH. The loss of GSH in the nucleus is evident in the majority 
of experimentally induced cataract.26 The loss is mainly attributed to the oxidation of the 
active reduced form of glutathione (GSH) into the inactive oxidized form GSSG. It is also 
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notable that the lens normally functions in an environment where oxygen is tightly 
controlled.44 This is reported to be necessary in preserving the lens transparency as 
experiments run in hyperbaric oxygen were shown to reduce GSH content and induce 
cataract formation.45 
1.4 Who is affected? Statistics on cataract 
Cataract is the leading cause of blindness worldwide and it is primarily a disease of the 
elderly given that 95% of cataracts are senile.46 The recent advances in medicine and 
healthcare services have led to an increase in the average lifespan worldwide. This 
unsurprisingly has led to higher number of people who develop cataract during their lifetime. 
In 2010, global figures estimated that approximately 11 million people were blind due to 
cataract while 35.1 million were visually impaired.47,48 In the UK, visual impairment is 
prevalent with cataract accounting for one third of the cases.47 It is estimated that 30% of 
people aged 60 and above are visually impaired in one or both eyes because of cataract.47 In 
England, approximately 400,000 cataract surgeries were performed annually by the NHS in 
2015.47 This number is projected to increase by 50% by 2035.47 In the US, 24 million people 
aged over 40 are affected by cataract and half of Americans aged 80 develop cataract.46 The 
annual spending on cataract treatment in the US amounts to $10.7 billion which include the 
cost of diagnosis, surgery, vision aids and other associated medical interventions.46 
1.5 Cataract Surgery 
To date, surgery remains the only effective treatment for cataract once it develops.27 Cataract 
surgery involves the removal of the cataractous lens and replacing it with an intraocular lens 
implant that is positioned inside the capsular membrane.49 Phacoemulsification is currently 
the standard surgical technique for cataract worldwide and represent 99.7% of cataract 
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operations performed in the NHS.46 The process involves the emulsification of the affected 
lens by ultrasonic waves and subsequently aspirating the lens as a fluid.49 Other forms of 
surgeries are intracapsular, extracapsular and manual small incision cataract extraction.49 
Although cataract surgeries are highly successful, the procedure still comes with 
complications such as posterior capsular opacification (PCO), capsular tear, endophthalmitis 
and retinal detachment.42 PCO is an abnormal growth of the remaining epithelial cells on the 
posterior capsular membrane after surgery; often referred to as secondary cataract which, in 
many cases, requires further surgical intervention.50 Additionally, to date there is no single 
implant model that can replicate the image quality and the capacity to alter focus of the 
biological lens.51 A significant drawback to surgery is its limited accessibility in the 
developing countries and the long waiting times in the developed world as the demand on 
surgery increases which adversely impacts the quality of life for the waiting patients.52 For 
these reasons, there is a growing interest in developing a therapeutic means of reversing, or 
at least halting, the progression of cataracts. It has been predicted that delaying the onset of 
cataract by 10 years would result in decrease in surgery need by 50%.29,53    
1.6 The current treatments and the prospects of future 
medications 
To date, there is no pharmacological treatment to reverse cataract, but efforts have been 
made to search for new therapeutics that can delay its onset. Delaying cataract progression 
can have positive impact on both the patients’ quality of life and the cost of healthcare spent 
on cataract treatment. The availability of surgery alternative will alleviate the burden on 
healthcare services and increase the affordability of cataract treatment worldwide. Over the 
past few decades, many drugs were proposed as potential cataract treatments with a great 
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emphasis on the relief of oxidative stress as a means of halting the progression of the disease. 
In the following sections a summary of the most common proposed drugs will be discussed. 
1.6.1 Carnosine 
L-Carnosine is a naturally occurring dipeptide (-alanyl-L-histidine) that has been recently 
marketed for cataract prevention in the form of a prodrug N-acetylcarnosine (NAC) as 1% 
eye drops.54 The drug is commercially available under the name Can-C™ that is intended for 
eye lubrication with the marketed off-label benefit of cataract prevention.55 NAC is more 
soluble than the parent compound and can pass through the cornea before being metabolised 
in the aqueous humour by carnosinase into active L-carnosine.54 In-vitro and in-vivo studies 
have shown that L-carnosine is a powerful water-soluble antioxidant and prevent against cell 
membrane lipid peroxidation.27 Babizhayev et al. carried out an experiment in which NAC 
was used as eye drops in 50 canine eyes and compared the results to 40 control eyes after 6 
months of treatment.56 The results obtained from slit image and retro-illumination 
photographs showed improvement in the lens clarity in 96% of the treated eyes.54 A 
randomised double-blind clinical trial of NAC was performed on 49 patients with an average 
age of 65 where they received NAC eye drops twice a day or a placebo.57 The eyes were 
assessed on several criteria such as best corrected visual acuity (BCVA), glare sensitivity, 
and lens clarity based on slit image and retro-illumination photographs. After 6 months of 
treatment, 90% of the NAC treated group showed BCVA improvement, 89% showed glare 
sensitivity improvement and the clarity of the treated lens improved in 42% of treated eyes. 
Similar results were also obtained after 2 years of NAC treatment.57 Although the results 
were promising, many limitations were noted for the study including the limited number of 
patients, low statistical power, and being carried at two-different time points where many 
patients dropped out of the trial at the latest point (45%). However, in another in-vitro study 
carried out on cultured porcine lenses, L-carnosine was shown to have no or limited 
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antioxidant activity.42 The study also showed that it does not protect human lens epithelial 
cells against hydrogen peroxide induced oxidative stress.42 The study finally concluded that 
L-carnosine is more of an anti-glycating agent than an antioxidant one and warned of L-
carnosine’s potentially damaging effects to the glutathione system if used in normal glucose 
levels.42   
1.6.2 Multivitamins 
Some vitamins such as ascorbic acid and vitamin E are known for their protective roles in 
preventing protein aggregation in the lens by the inhibition of formation of protein disulphide 
bonds.27 In-vitro studies showed that ascorbic acid was able to protect rat lenses against 
oxidative stress. Similarly, in-vivo experiments on diabetic rats, which notably have a 
different complement of crystallins to humans, showed significant delay in cataract 
progression when their diet was supplemented with 1% ascorbate.58 Robertson et al. showed 
that decreased self-reported consumption of ascorbic acid or vitamin E correlated with high 
incidence of lens opacity in 175 patients aged over 55.59 Another non controlled prospective 
study found that patients who took multivitamins experience less cataract risk after a five 
years period.60 However, blood levels of vit E and ascorbate linked poorly with cataract 
progression. A clinical trial concluded that long term use of antioxidant supplements is of 
limited benefit in populations with balanced diet.61 Vitamin E, Cataract, and Age-Related 
Maculopathy Trial (VECAT) carried out on 1193 patients that daily consumption of vitamin 
E (500 IU) did not inhibit the progression of any of the three main cataract types.62 
1.6.3 Aspirin, paracetamol and ibuprofen 
Aspirin was first noted to delay cataract progression from a study intended to treat 
rheumatoid arthritis in diabetics.63 Subsequent experiments showed some evidence of aspirin 
and other analgesics in protecting against cataract. Aspirin was shown to provide in-vitro 
protection of rat lenses against lens opacity induced by cyanates.64 An in-vivo study showed 
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that aspirin, paracetamol and ibuprofen counter the progression of cataract in diabetic rats.65 
It is not currently known how these analgesics delay cataract development and several 
mechanisms have been suggested. Aspirin like drugs are known for their blood thinning 
actions which may improve the blood flow providing the lens with more nutrients and 
antioxidants.1 Aspirin (acetyl salicylic acid) is an acetylating agent which could in turn acetyl 
proteins protecting them from being modified by cyanates, steroids or glucose.66 Aspirin was 
suggested to have an indirect effect of increasing GSH concentrations in the lens.66 A study 
carried out on 909 patients in England reported that the risk in cataract progression is halved 
in the group treated with aspirin and aspirin like drugs.67 That being said, other studies failed 
to find a relationship between aspirin and protective effects against cataract.68 One 
significant disadvantage of aspirin therapy is that it requires the use of large oral doses (1.5 
g/day) to achieve significant cataract protection.1 This undoubtedly poses great risk for 
developing the common non-steroidal anti-inflammatory drugs (NSAIDs) associated side 
effects such as gastritis, peptic ulcers, renal failure and cardiovascular diseases. Even the 
topical application of such drugs is associated with adverse effects of burning sensation, 
corneal defects, conjunctival hyperaemia and corneal melt.69,70 This renders the use of such 
drugs for long term, that is needed for cataract prevention, highly problematic. Another 
discouraging factor is the lack of incentive for pharmaceutical companies to carry out long 
term studies on the efficacy and safety of such drugs as most of these are out of patent.71 
1.6.4 Lanosterol  
Perhaps one of the most interesting and potentially paradigm shifting results was the studies 
carried out by Zhao et al. and Makley et al. on lanosterol and similar sterols.72,73 In these 
studies, lanosterol was reported to have the ability to reverse cataract by dissolving protein 
aggregates and amyloid-like fibril proteins in in-vivo and ex-vivo animal models with 
congenital cataracts. This was attributed to the ability of lanosterol to bind to α-crystallin 
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and enhance its chaperone like activity. Subsequent studies were carried out expanding the 
results on different mouse models developing congenital cataracts.74,75 Lanosterol was 
subsequently marketed in the form of eye drops for cataract treatments. However, recent 
studies on these compounds reported the inability of lanosterol to reverse cataract in various 
experimental models. In one study, 40 human lenses developing senile cataract were 
incubated for six days in 25 mM lanosterol solution and the results showed no effect of the 
compound on reversing cataract.76 A study carried out on a single patient with juvenile 
nuclear cataract failed to show any improvement after administering lanosterol eye drops (5 
mM) for 8 weeks.77 Furthermore, a very recent study showed that lanosterol liposomes (15 
mM) failed to reverse or delay the progression of cataract in in-vitro rat lenses against 
induced cataracts.78 Together these results show that it is still early to conclude whether 
lanosterol and related compounds provide any benefit in the realm of cataract treatment.  
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1.7 Nanotechnology for cataract  
Nanotechnology is rapidly developing for the diagnosis and treatment of a plethora of 
diseases including ocular diseases.79 This is attributed to the extraordinary ability of nano 
systems to control the delivery and release of various drug entities hence significantly 
enhance the pharmacokinetics and pharmacodynamics of therapeutics.79 Nano systems can 
harbour multiple drugs in the same time and their surface can be modified with ligands that 
have various functionalities.79 Research on the use of nanotechnology for cataract treatment 
has been mainly focused on enhancing lens penetration, retention and release profiles of 
antioxidants and other drugs known for their potential to delay cataract. In that sense, nano 
systems in the field of cataract prevention and treatment were more of vehicles or vectors to 
deliver other entities. Cetinel and Montemagno have reviewed the use of several polymeric 
(e.g. PLGA nanoparticles) and lipidic (e.g. liposomes) nano systems in enhancing the 
bioavailability or efficacy of antioxidants and molecular chaperones in various cataract 
models.80 In the following sections, the potential of one type of nanoparticles to act as a 
therapeutic on its own rather than just a vehicle for other drug entities is discussed. 
1.8 Cerium oxide nanoparticles (nanoceria) as a potential 
cataract therapeutic 
Cerium (Ce) is one of the lanthanides or rare earth metals positioned in the f-block of the 
periodic table.81 The chemistry of lanthanides is unique because of the presence of 4f 
electrons that are sandwiched between 4d and 5p electrons isolating them from the atom’s 
environment.81,82 This configuration provides lanthanides with exclusive electronic, catalytic 
and magnetic properties that are not found in other metals. Such properties are currently 
heavily explored and used in various industrial applications such as magnets production, 
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electric motors, LCDs, surface polishing, catalysis, diagnostics, radiation therapy, 
biosensing, and bioimaging.82 
Cerium, which is the first element of rare earths with 4f electrons, has garnered great 
attention for its versatility of use in various biological, chemical and material science 
applications. The oxidation of cerium creates cerium oxide (CeO2) crystals with a face 
centred cubic fluorite structure which possesses remarkable redox and catalytic properties.81 
These properties have already been utilised in various applications in diverse products such 
as solar cells,83 oxygen sensors,84 catalysis,85 UV filters,86 and polishing.87 Cerium oxide 
(CeO2) nanoparticles or “nanoceria”, have also shown potential for the treatment and 
prevention of various disorders including cancers,88 inflammatory diseases,89 
neurodegenerative disorders,90 retinopathy,91 and cardiovascular dysfunctions92 owing to the 
nanoparticles’ powerful antioxidant activity. 
1.8.1 Synthesis of cerium oxide nanoparticles 
Cerium oxide nanoparticles can be synthesised using various techniques such as aqueous co-
precipitation, hydrothermal decomposition, solvothermal decomposition, electrochemical 
deposition, flame spray, sol-gel, and micellar or microemulsion synthesis.93–96 In these 
methods, various parameters can be systematically altered to control the size, shape, surface 
charge, and the coating material of the produced nanoparticles which significantly alters their 
behaviour. Therefore, the choice of the synthesis method is critical for fitting the intended 
application. For example, aqueous synthetic methods are more suitable for producing 
nanoparticles for use in aqueous media. 
1.8.2 Cerium oxide structure and redox properties  
The potential cerium oxide nanoparticles have shown in treating various medical conditions 
can be attributed to their remarkable redox and antioxidant properties. In CeO2 crystals, 
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cerium atoms can exist in two different oxidation states; reduced (Ce3+) and oxidised 
(Ce4+).97 The oxidised state is the preferred stable form in the crystal structure of cerium 
where each cerium atom is coordinated with eight neighbouring oxygen atoms, and each 
oxygen atom is coordinated with four neighbouring cerium atoms.98 However, surface 
defects are normally present on the surface of the crystals and these are associated with Ce3+ 
existence (Figure 1-3). The decrease in the positive charge is compensated by the arising of 
oxygen vacancies on the crystal surface. It is now known that the smaller the particle size of 
CeO2 nanoparticles, the higher the number of defects and the higher Ce
3+/Ce4+ ratio.81 Such 
ratio can be studied by means of X-ray photoelectron spectroscopy and UV–visible 
absorption spectroscopy.81 
The co-existence of Ce3+, Ce4+ and O2 vacancies in the same crystal lattice enables the 
nanoparticles to act in a versatile way in redox reaction as either an oxidiser or a reducer 
depending on the environment. In another words, the electronic configuration of cerium can 
alternate between Ce3+ and Ce4+ to best fit the environment.81 When CeO2 loses oxygen in 
the process of forming surface Ce3+, the formed crystal retains its original fluorite structure 
and is often referred to as CeO2-x where x is the number of oxygen vacancies.
98 
 
Figure 1-3 Cerium oxide crystal structure.99 
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1.8.3 Cerium oxide multi-enzyme mimetic properties  
Cerium oxide nanoparticles redox properties have been found to mimic key natural 
antioxidant enzymes such as superoxide dismutase (SOD) and catalase.100,101 SOD converts 
superoxide into H2O2 and water. A study has shown that this activity could be achieved in-
vitro by CeO2 nanoparticles owing the ease of transition between Ce
4+ and Ce3+ valence 
states and a mechanism was proposed as shown in the following equations:101  
O2
- + Ce4+→ O2 + Ce
3+ 
O2
- + Ce3+ + 2H+ → H2O2 + Ce
4+ 
A more elaborative mechanism for superoxide dismutation by CeO2 has been subsequently 
proposed by Celardo et al (Figure 1-4).102 The catalytic rate of this reaction exceeds that 
known for SOD itself.101  
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Figure 1-4 Proposed mechanism of superoxide dismutation by cerium oxide.102 
 
Similarly, CeO2 nanoparticles were shown in-vitro to mimic catalase activity that is known 
for breaking H2O2 into oxygen and water. A mechanism has been proposed as follows:
103 
H2O2 + Ce
3+
→ H2O + Ce
4+ 
H2O2 + Ce
4+
→ O2 + H2O + Ce
3+ 
In-vitro testing has shown that SOD activity is associated with higher Ce3+/Ce4+, while 
catalase-mimetic activity is more pronounced with higher Ce4+/Ce3+ ratio.81,100,101 It is 
noteworthy that the SOD activity of CeO2 nanoparticles generate H2O2 which is more lethal 
for the cells compared to superoxide.104 However, the generated H2O2 can enter the catalase 
cycle of CeO2 and this damage is often negated. This makes the nanoparticles powerful 
antioxidants with the ability to nullify multiple kinds of ROS simultaneously. Various 
studies have shown the effect of many factors such as particle size, buffer species and pH on 
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the enzymatic activity of CeO2 nanoparticles.
81 One of the most biologically relevant factors 
is the presence of phosphate buffer that is reported to increase the catalase activity and 
decrease SOD activity.105 This has to be considered given that the use of such buffers is 
ubiquitous in in-vitro and in-vivo studies. In addition to these enzyme mimetic activities, 
CeO2 has shown that it is able to scavenge for multiple ROS and reactive nitrogen species 
(RNS) such as hydroxyl radical and nitric oxide radical (as reviewed).81  
1.8.4 Cerium oxide for oxidative stress-related diseases 
 The versatility of cerium oxide nanoparticles in scavenging for multiple ROS makes them 
superior to traditional antioxidants or enzymes whereas the latter often scavenge for a single 
kind of free radicals. This, in addition to the nanoparticles being able to recycle themselves, 
has encouraged researchers to investigate the use of the nanoparticles for the treatment of 
oxidative stress related conditions.81 The nanoparticles have shown promising results in-vivo 
and in-vitro in many of these diseases such as Parkinson’s disease, Alzheimer’s disease, 
cardiovascular diseases and diabetes where oxidative stress is reported to play a major role 
in their progression.92,106,107 
Additionally, cerium oxide nanoparticles have also shown promise in retinal diseases where 
photoreceptor cells have the highest oxygen consumption rate of any cells in the body and 
are constantly exposed to hazardous effects of oxidative stress and incident photons. The 
retinal diseases associated with oxidative stress include retinal detachment, diabetic 
retinopathy, and macular degeneration which can lead to partial or complete blindness.81 
Chen et al. have shown in in-vitro and in-vivo experiments that cerium oxide nanoparticles 
protect against retinal degeneration induced by peroxides and hence protect the retinal 
morphology and function.108 The protection mechanism was attributed to the ability of 
cerium oxide nanoparticles to decrease ROS levels and upregulate the expression of 
neuroprotective genes.108 
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Despite the promising results of cerium oxide nanoparticle in the treatment of oxidative-
stress related conditions, their use in cataract treatment remains largely unexplored. 
Pierscionek et al. have shown that negatively charged cerium oxide nanoparticles (5.5 nm) 
are not genotoxic in human lens epithelium when used with very low concentrations: 5 and 
10 µg/ml.109 However, their potential to provide anti-cataractogenic properties was not 
further investigated and hence requires further study.  
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1.9 Project aims 
Finding an alternative for surgery will create a new dawn for cataract: the main cause of 
blindness worldwide. So far, surgery remains the only effective treatment which suffers from 
perioperative and postoperative complications, limited accessibility to patients in the 
developing world and the increased economic burden on health services as the aging 
population is increasing. 
The aim of this project is to thoroughly investigate the potential of cerium oxide 
nanoparticles (nanoceria) to provide anti-cataractogenic effects in-vitro. To achieve this the 
following objectives were set: 
1- To synthesise CeO2 nanoparticles and optimise their properties for biomedical 
applications. For this, various considerations have to be taken into account. The size, 
the coating and the aqueous stability in biological media have to be optimised to 
ensure consistency of the results in subsequent biological testing. A strategy to 
fluorescently label the nanoparticles for biological imaging studies is needed with 
minimal alterations to the nanoparticles’ properties. 
2- To thoroughly investigate the safety and toxicity of the optimised nanoparticles in 
the metabolically active cells of the lens: the human lens epithelium. Various cellular 
parameters in response to different concentrations of the nanoparticles will be 
assessed for the first time. These include cellular proliferation, cell morphology, cell 
membrane integrity, mitochondrial morphology, mitochondrial membrane potential, 
cellular ATP level, basal ROS level, caspases activation, and cell membrane 
asymmetry.  
3- To study the uptake, its mechanism and subcellular localisation of the nanoparticles 
in the lens epithelial cells. 
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4- To study if these nanoparticles provide anti-catarctogenic effects in the human lens 
epithelial cells. Protection against induced oxidative stress will be studied in addition 
to the ability of the nanoparticles to mimic the catalase enzyme in the cells. The effect 
of the nanoparticles on glutathione will be investigated. Finally, the ability to block 
one of the major post-translational modifications in cataracts, glycation, will be 
studied in-vitro. 
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2 Development of cerium oxide nanoparticles for 
biomedical applications 
2.1 Introduction 
Cerium oxide (CeO2) nanoparticles “nanoceria” are rare earth metal oxides with multiple 
applications across diverse applications such as solar cells,83 oxygen sensors84, catalysis,85 
UV filters,110 and surface polishing.87 Biomedically, nanoceria have been investigated over 
the last decade, and have shown potential for the treatment and prevention of various 
disorders including cancers,88 inflammatory diseases,89 neurodegenerative disorders,90 
retinopathy,91 and cardiovascular dysfunctions.92 The therapeutic effects of CeO2 
nanoparticles are attributed to their antioxidant properties and their capability to eliminate 
reactive oxygen species (ROS).81 These antioxidant attributes originate from the presence of 
surface crystal defects and their associated oxygen vacancies allowing cerium ions to co-
exist in and transition between trivalent and tetravalent states (Ce3+ and Ce4+), a transition 
that is dependent on the ambient environment.81,111 This enables nanoceria to mimic key 
antioxidant enzymes such as catalase and superoxide dismutase. Hence, in order to maximise 
the antioxidant activity of nanoceria the number of surface defects has to be increased 
leading to concomitance increase in the surface Ce3+ and oxygen vacancies.112 This can be 
achieved by reducing the particle size of the nanoparticles which gives rise to a fundamental 
problem namely aggregation. Aggregation is caused by the increase in the surface energy of 
the nanoparticles leading to excessive inter-particular interactions such as van der Waals 
forces.88,113 In addition to the loss of activity induced by the reduced surface area, 
aggregation results in a formulation with poor colloidal stability causing sedimentation of 
the nanoparticles in physiological media. Consequently, this leads to exposure of cellular 
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monolayers to a higher concentration than the stated bulk concentration, and so 
compromising the reliability of in vitro experiments.114 Efficient dispersibility of 
nanoparticles in media is therefore of paramount importance in order to draw accurate 
conclusions about the biological effects of the employed nanoparticle concentrations. 
Unfortunately, many of nanoceria formulations employed in biomedical studies reported in 
the literature are conducted on poorly characterised formulations where proper colloidal 
stability evaluation is lacking. This in turn leads to conflicting data when therapeutic and 
toxicological evaluations of nanoceria are concerned. Hence, in this study the aim was to 
aqueously produce thoroughly characterised nanoceria with a well-defined small particle 
size and proper colloidal stability before studying them in-vitro. Coating nanoceria with 
different materials has been shown to improve colloidal stability through minimising surface 
attractive interactions.113 However, this is often accompanied by drastic changes in particle 
size, surface charge, the use of biologically incompatible coatings, complex multistep 
synthesis, organic synthetic routes, in addition to the lack of sufficient colloidal stability data 
of the functionalised nanoceria.112,113,115 
In this chapter, the successful formulation and characterisation of aqueously monodisperse 
and ultrasmall (< 5 nm) nanoceria coated with ethylene glycol and ethylene glycol acetates 
(EGCNPs) is described using a simple, aqueous and scalable one pot co-precipitation 
reaction. Ethylene glycol was chosen as a coating material because of its safety, 
hydrophilicity, biocompatibility, and low cost making it a suitable coating material for 
biological use.113 The formulation demonstrated superior colloidal stability in aqueous 
solution and the nanoparticles were readily dispersible from dried powder with mild 
agitation. Finally, unique multi-coloured photoluminescence properties of the nanoparticles 
across the visible light spectrum are reported, and the photoluminescent properties were 
enhanced by europium doping to facilitate biomedical imaging studies.  
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2.2 Materials and methods 
2.2.1 Synthesis of cerium oxide nanoparticles 
Ethylene glycol coated cerium oxide nanoparticles (EGCNPs) were formulated using a 
modified alkaline precipitation method.113 Briefly, cerium(III) acetate hydrate (20 mmol, 6.3 
g, Sigma Aldrich, UK), ethylene glycol (10 ml, 99.99 % purity, Fisher Scientific, UK), and 
HCl (0.2 ml, 1 M, Fisher Scientific, UK) were added to distilled water (100 ml), and left to 
homogenize (15 min at 40°C).  Ammonia solution (35%, Fisher Scientific, UK) was then 
added dropwise until the pH reached 9.6 and a pale-yellow precipitate was immediately 
formed. This initial precipitate turned dark purple after stirring (ca. 10 min). The reaction 
was left stirring for 2 h and a colour change to pale yellow was observed. The reaction 
mixture was diluted with ethanol (50 ml, Fisher Scientific, UK), and the precipitate was then 
collected by centrifugation (1500 rcf, 5 min), washed with distilled water (50 ml x 2) and 
ethanol (50 ml x 1) and left to dry in an oven at 60°C for 12 h. After drying, the precipitate 
was ground into fine powder in an agate mortar and stored in an airtight container. For 
comparison, non-coated cerium oxide nanoparticles were prepared as before without the 
addition of ethylene glycol to the reaction mixture. Europium-doped nanoceria (EuCNPs) 
were synthesized as above by adding europium nitrate (99.99 %, Sigma Aldrich, UK) to the 
initial reaction mixture with a Ce : Eu molar ratio of 1:0.2.116  
2.2.2 Transmission electron microscopy (TEM) 
TEM was used to determine the morphology and particle size of the nanoparticles (EGCNPs 
and EuCNPs). The nanoparticles were suspended in distilled water (1 mg/ml) and sonicated 
for 5 min. 50 µL of the suspensions were placed on holey carbon coated 300 mesh copper 
grids (Agar Scientific, UK), left to dry and visualised using TEM operating at 200 kV (JeoL-
2010, Japan). The average particle size was determined by measuring the diameter of 100 
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particles from different spots on the grid using ImageJ software (National Institutes of Health, 
USA). 
2.2.3 Powder X-ray diffraction (XRD) 
The crystalline structure of the powder EGCNPs nanoparticles was determined from the 
diffraction spectra obtained using a powder X-ray diffractometer (X’Pert PRO, PANalytical, 
UK) which operated with Cu Kα1 radiation source (λ=1.5406) at 30 mA and 40 kV at 
continuous scanning mode. The scan range operated from 20 - 70 (2θ) with a step size of 
0.017° and scan step time of 50.16 seconds. EGCNPs crystallite size (dXRD) was calculated 
from the characteristic diffraction peak (1 1 1) using the Scherrer equation6:  
dXRD = 
0.94λ
FWHM cos 𝜃
 
where λ is the x-ray radiation wavelength, θ is the Bragg diffraction angle for (1 1 1) plane, 
and FWHM is full width half maximum of the diffraction peak at (1 1 1). 
2.2.4 Ultraviolet-visible spectrophotometry (UV-vis) and fluorescence studies 
UV-vis absorption spectra of diluted nanoparticles water dispersions were obtained using a 
spectrophotometer (Cary 8454 UV-Vis, Agilent, USA) operating at wavelengths between 
200 - 800 nm with 1 nm resolution. The suspensions were measured in quartz cuvettes (1 
cm, Agilent, USA) and distilled water was used as a blank. Emission and excitation spectra 
of EGCNPs and EuCNPs in water were measured in a flat-bottom black 96-well plate using 
a spectrofluorometer (Clariostar, BMG Labtech, Germany). Fluorescence images of 
EGCNPs dry powder placed on glass slide was acquired using confocal laser scanning 
microscopy (Leica, Germany) using 20x dry objective and appropriate excitation laser lines 
and emission filters. Fluorescence microscope images of EuCNPs using RFP-compatible 
settings (excitation at 531 nm/40 nm, emission at 593 nm/40 nm) using EVOS FL 
epifluorescence microscope (Thermo Fisher, UK).  
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2.2.5 Fourier-transform infrared spectroscopy (FTIR) 
Fourier transform infrared-attenuated total reflectance (FTIR-ATR) spectra were acquired 
using Cary 630 FTIR spectrometer (Agilent, USA). The dry nanoparticles were placed on 
the diamond ATR and measurements were taken between 650 and 4000 cm-1 with a 
resolution of 4 cm-1. Eight sample scans were performed for each sample. 
2.2.6 Scanning electron microscopy-energy dispersive x-ray spectroscopy 
(SEM-EDX) 
SEM-EDX (Jeol JSM-7100f, Japan) was used to identify the elemental composition of the 
prepared nanoparticles. A thin layer of dry nanoparticles was spread on a carbon tape placed 
on an aluminium stub (13 mm in diameter) and examined using the secondary electron 
detector with an accelerating voltage of 10-15 kV and working distance of 10 mm. The spot 
size was adjusted so that the dead time was between 30 – 60%. No sample coating was 
required. EDX spectra were acquired and processed using Aztec software (version 2011, 
Oxford Instruments, UK). 
2.2.7 Thermogravimetric analysis - gas chromatography – mass spectrometry 
(TGA-GC-MS) 
The amount and composition of the surface coating of the nanoparticles were confirmed by 
thermogravimetric analysis (TGA 4000, PerkinElmer, USA) connected to a gas 
chromatography-mass spectroscopy system (GC Clarus 580 – MS Clarus SQ 8S, 
PerkinElmer, USA). Briefly, 16 mg of the nanoparticles were weighed in a TGA crucible 
and heated from 30 °C to 700 °C with a heating rate of 20 °C/min and gas flow of 30 ml/min. 
GC-MS sampling was set to be triggered after 9.5 min from the start of the run (at 200 °C). 
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2.2.8 Dynamic light scattering (DLS) and zeta potential 
A stock water dispersion of the nanoparticles was prepared (5 mg/ml) and sonicated for 10 
min at room temperature. The dispersion was then diluted to a final concertation of 400 
µg/ml in distilled water, phosphate buffer saline (PBS) or Eagle's minimum essential 
medium (EMEM) supplemented with foetal bovine serum (FBS, 20%) and pH was 
maintained at 7. The diluted solutions were then placed in disposable plastic cuvettes or 
quartz zeta flow cell for particle size analysis or zeta potential measurements respectively. 
The particle size and zeta potential measurements were taken using dynamic light scattering 
(DLS) (Nanoplus, Particulate Systems, USA) at 25 °C. Each DLS measurement consisted of 
20 accumulations. For zeta potential measurement, the Smoluchowski equation was 
employed to convert the electrophoretic mobility to zeta potential as follows: 
Electrophoretic mobility =  
𝜀𝑟 𝜀0  ζ  
η
 
Where εr is relative permittivity/dielectric constant, ε0 is permittivity of vacuum, ζ is zeta 
potential and η is viscosity at experimental temperature. All measurements were done in 
triplicates and the data is represented as mean ± standard deviation (SD)  
2.2.9 Colloidal stability and sterilisation 
The colloidal stability (i.e. the resistance of the nanoparticles against precipitation in solution) 
of EGCNPs and non-coated nanoceria was measured by allowing nanoparticle dispersions 
(400 µg/ml) to settle over 7 days at room temperature. The concentration of the nanoparticles 
in the supernatant was measured each day using a spectrophotometer (Cary 8454 UV-Vis, 
Agilent, USA) at 300 nm. The nanoparticles were sterilised by filtration through 0.22 µm 
syringe filters (Millipore, USA). The amount of the nanoparticles lost in the filtration process 
was measured spectrophotometrically at 300 nm.  
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2.3 Results and discussion 
2.3.1 EGCNPs morphology and crystallinity (TEM and XRD)  
Ethylene glycol has the ability to complex with Ce3+ ions through coordination bonds with the 
hydroxyl (OH) groups, making the reaction homogenous for the ensuing ammonia precipitation 
step.113,117 Coating nanoceria with ethylene glycol starting from a nitrate precursor has been 
reported previously to produce relatively large particle sizes (> 10 nm)  and significant 
polydispersity due to aggregation in both water and cell culture media that adversely impact 
biomedical applications.113 The ability to produce water dispersible ultra-small (< 5 nm) 
nanoceria is desirable as the size reduction with concomitant high surface to volume ratio 
increases both ROS deactivation capacity and regenerative properties of nanoceria.100,103 
Furthermore, smaller particle size provides better penetration into the cells compared to their 
larger counterparts.118 To obtain nanoparticles with these desirable properties, a modified 
synthetic process was employed where cerium(III) acetate hydrate was used as a starting 
precursor in an alkaline precipitation reaction. In this reaction, the acetate ligands esterified 
ethylene glycol forming monoacetate and diacetate derivatives as part of the coating 
according the following equations: 
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The produced formulation is referred to ethylene glycol and ethylene glycol acetates-coated 
nanoceria (EGCNPs). 
The morphology, particle size and crystallinity of EGCNPs were investigated using a 
transmission electron microscope (TEM). TEM micrographs of EGCNPs (Figure 2-1a and 
Figure 2-1b) show the nanoparticles with average core sizes of 4.0 nm ± 0.8 nm (histogram 
shown in Figure 2-1d). The images show mosaic-like patterns of monodisperse and well-
separated nanoparticles. This is caused by the presence of ethylene glycol which appears as 
transparent coronae in the TEM images because of its low electron density compared to 
electron-rich cerium oxide cores. On the other hand, non-coated nanoceria exhibited larger 
particle sizes (7 – 13 nm) with significant aggregation and lack of uniformity, highlighting 
the role of ethylene glycol coating in stabilising the synthesis (Figure 2-1c). 
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Figure 2-1 Transmission electron microscopic (TEM) images of nanoceria. 
(a) ethylene glycol-coated nanoceria (EGCNPs) at 20K and (b) EGNCPs at 100K magnification; both 
images show that nanoparticles are relatively uniform in size and well separated with near spherical 
morphology, (c) non-coated nanoceria (at 100k magnification) that exhibit significant clustering, 
irregularity and polydispersity, (d) A histogram showing size distribution of a hundred EGCNPs 
nanoparticles measured by TEM. 
 
The crystallinity of EGCNPs was confirmed by the presence of the crystal lattice fringes 
clearly identified in the high resolution TEM images as shown in Figure 2-2a. A line profile 
was plotted (Figure 2-2b) from which the d-spacing of the characteristic (111) plane was 
calculated to be 0.33 nm. This was in a close agreement with the lattice spacing value 
reported in the literature (0.31 nm) given the resolution limitation of TEM.  
(d) 
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Figure 2-2 High resolution TEM micrographs showing the lattice fringes. 
(a) and (b) EGCNPs, (c) A line profile plotting (of the blue line in image b) showing the d-spacing of 
the characteristic (111) lattice planes where it was measured to be 0.33 nm. 
 
Powder X-ray diffraction (XRD) data further confirmed the cubic fluorite crystalline 
structure of CeO2 which was in agreement with the structure reported in the literature 
(JCPDS No. 75–0390).109 The characteristic 2θ diffraction peaks at 28.4°, 33.3°, 47.3°, 56.12° 
correspond to the (111), (200), (220), and (311) planes respectively, and are annotated on 
the diffractogram (Figure 2-3). The d-spacing values of the aforementioned planes were 
3.137, 2.69, 1.91 and 1.63 nm respectively. The diffraction peaks of EGCNPs were 
significantly broader than those of non-coated nanoceria which is indicative of EGCNPs 
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smaller crystallite size.101 The crystallite size, calculated by applying the Scherrer equation 
on (111) diffraction peak was found to be 3.5 nm (a calculation is available in the appendix). 
This is close to the average particle size calculated from TEM images (4.0 nm). This 
difference between TEM and XRD measured sizes is expected as a crystallite (measured by 
XRD) is usually smaller than a particle which may be composed of multiple crystallites.119 
Additionally, in the case of a particle being composed of one crystallite, XRD provides more 
accuracy in measuring the particle size due to the high statistical power involved.119   
 
Figure 2-3 X-ray diffractogram displaying characteristic planes (annotated) typical of face-centered 
cubic fluorite structure of EGCNPs. 
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2.3.2 FTIR characterisation  
FTIR is utilised to identify the various functional groups in a given molecule based on the 
frequency of IR radiation absorbed by its specific bonds. Hence, the presence or the absence 
of specific bands and their relative intensities can provide valuable information about the 
structure of the compounds being studied.120 The FTIR spectrum for EGCNPs (Figure 2-4a) 
confirmed the structure of EGCNPs and this concurs with findings reported in the 
literature.121 The presence of ethylene glycol coating was indicated by the presence of two 
characteristic bands corresponding to methylene (CH2) stretching at 2950 and 2850 cm
-1 and 
a broad band from 3000 - 3600 cm-1 corresponding to (O-H) stretching.113 The (O-H) 
stretching band was significantly prominent compared to a non-coated formulation (Figure 
2-4b) indicating that the band pertains to additional (OH) groups from ethylene glycol and 
does not primarily arise from moisture adsorption on the surface.120  The intense band at 
1400 cm-1 can be assigned to bending vibration of adsorbed H2O molecules.
122 The bands at 
1550 cm-1 and 1400 cm-1 correspond to C-H bending of the methylene group and Ce-O 
stretching respectively.121  
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Figure 2-4 FTIR analysis of nanoceria. 
(a) EGCNPs FTIR confirming the presence of ethylene glycol and ethylene glycol acetates coating as 
indicated by the appearance of methylene stretching as two small peaks in the spectra, (b) non-coated 
nanoceria FTIR showing weak OH stretching and lack of methylene stretching. Transmittance is 
presented as a percentage. 
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2.3.3 UV-vis characterisation  
The UV-vis spectrum of EGCNPs aqueous dispersion showed two main absorption peaks at 
255 nm and 300 nm (Figure 2-5) signifying the presence of mixed state valence. Ce3+ is 
known to absorb light between 230-260 nm while Ce4+ absorbs light in the region of 300 – 
400 nm.88 A typical nanoceria crystal contains cerium predominantly in its oxidized state 
(Ce4+). As the crystal size decreases, surface defects associated with oxygen vacancies arise, 
increasing Ce3+ at the surface. The co-existence and transition of the cerium ions between 
the two oxidation states is what endows the nanoparticles with their free radical deactivation 
ability where the Ce4+/Ce3+ ratio is critical in determining the mechanism by which they 
scavenge for ROS.103  
 
Figure 2-5 UV-visible spectrum of EGCNPs showing absorption at 255 nm and 300 nm confirming the 
presence of surface Ce3+. 
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2.3.4 SEM-EDX characterisation  
The elemental composition of EGCNPs was confirmed by scanning electron microscopy 
equipped with energy dispersive X-ray spectroscopy (SEM-EDX). As shown in the EDX 
spectrum in Figure 2-6, Mα and Lα characteristic X-ray emission peaks for cerium (
58Ce) 
were observed at 0.88 KeV and 4.83 KeV respectively. Kα X-ray emission at 0.52 KeV 
confirmed the presence of oxygen in the CeO2 lattice.  
 
Figure 2-6 SEM-EDX analysis of EGCNPs. 
(a) SEM micrograph of a cluster of EGCNPs, (b) EDX spectrum of the point highlighted in the SEM 
micrograph showing characteristics peaks of cerium and oxygen of CeO2. 
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2.3.5 EGCNPs coating characterisation by TGA-GC-MS 
The presence and composition of the surface coating of EGCNPs were confirmed using 
TGA-GC-MS as shown in Figure 2-7 and Figure 2-8. Two main regions of weight loss were 
observed. The initial weight loss starting from 100 °C to 150 °C (10%) can be attributed to 
the loss of residual water and the loosely bound outermost layer of the coating, while the 
second weight loss (20%) indicated full decomposition of the coating from 200 -700 °C. The 
components of the vaporised coating were then separated by gas chromatography and 
analysed by mass spectroscopy. Mass spectrometry data (Figure 2-8) revealed that the 
coating was a mixture of three compounds; ethylene glycol, ethylene glycol monoacetate 
and ethylene glycol diacetate. This modified hybrid coating provided the nanoparticles with 
additional carbonyl groups conferred by the acetate ligands and these are hypothesised to 
play an important role in the aqueous stability of nanoceria through hydrogen bonding with 
water molecules. Moreover, the additional ethylene glycol acetate ligands are longer than 
pure ethylene glycol coating and longer surface ligands are generally associated with 
enhanced stability of the nanoparticles through the steric hindrance effect.123,124  
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Figure 2-7 Thermogravimetric analysis (TGA) of EGCNPs showing two main weight loss regions. 
The decomposed coating was separated by gas chromatography and analysed by mass spectrometry. 
The arrow indicates the time at which GC-MS analysis was triggered. Chromatogram peaks at 2.1, 3.1 
and 4.5 min correspond to ethylene glycol, ethylene glycol monoacetate and ethylene glycol diacetate 
respectively.  
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Figure 2-8 Gas chromatography - mass spectrometry analysis (GC-MS) of EGCNPs coating after 
decomposition in TGA.  
The chromatogram is showing the three main peaks separated from the decomposed coating and mass 
spectra of the peaks are displayed confirming the composition to be ethylene glycol, ethylene glycol 
acetate and ethylene glycol diacetate. Key m/z values are as follows:  
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In order to ensure that the presence of the modified ethylene glycol surface coating does not 
inhibit the antioxidant and auto-regenerative properties of EGCNPs by blocking the access 
of ROS to the surface cerium oxide cores, a solution of EGCNPs (pH = 7) was treated with 
H2O2 and an immediate colour change from colourless to orange was observed (Figure 2-9). 
This indicated the oxidation of surface Ce3+ (colourless) into Ce4+ (orange), reducing the 
hydrogen peroxide in the process.81,125 The reduced colourless solution associated with the 
presence of surface Ce3+ was successfully retrieved by either boiling (ca. 5 min) or leaving 
the oxidised solution at ambient conditions (10 days). The retrieved colourless solution (Ce3+) 
was able to react again with freshly added H2O2 turning orange.
125  Such transition between 
Ce3+ to Ce4+ was further accompanied by a corresponding red shift in the UV-Vis absorbance 
spectrum as shown in Figure 2-9. Such reversibility in the behaviour of nanoceria is crucial 
for its biomedical activity where the nanoparticles can alternate between catalase and 
superoxide dismutase (SOD) like activities depending on the ambient environment.81 Hence, 
the results clearly indicate that the acetylated ethylene glycol coating does not interfere with 
the redox and reversible properties of EGCNPs rendering them promising for in vitro studies.  
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Figure 2-9 Acetylated ethylene glycol coating does not interfere with the antioxidant and regenerative 
properties of EGCNPs.  
Oxidation of Ce+3 (colourless) into Ce+4 (orange) upon hydrogen peroxide addition. A red shift in the 
UV absorption of the resulting orange solution corresponding with this change was observed; 
colourless Ce+3 (blue spectrum), Ce+4 (red spectrum). The reduced colourless solution (Ce+3) was 
retrieved by either boiling or leaving the oxidised solution at ambient conditions (10 days). The reduced 
solution (Ce+3) reacted again with freshly added hydrogen peroxide turning orange. 
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2.3.6 EGCNPs photoluminescence and optical properties  
Fluorescence studies revealed that EGCNPs exhibited unique multi-coloured emissions that 
extended from the UV to the red region of the visible spectrum. Figure 2-10a and Figure 
2-10b show EGCNPs emissions in the blue, green and red regions of the visible spectrum 
when excited with 390, 450 and 513 nm respectively, and Figure 2-10c and Figure 2-10d 
show the blue and green emissions detected in both dispersion and powder forms when 
excited with the appropriate wavelengths. The shorter wavelength emission (blue) was 
relatively broad with the peak tail reaching beyond 600 nm (Figure 2-10a). Both excitation 
and emission spectra were considerably broad which made the detection of nanoparticles 
highly tunable in a fashion similar to quantum dots (i.e. multiple excitations and emission 
wavelengths can be used for their detection).126 For example, when excited at 270 nm, 
EGCNPs maximum emission was blue-shifted with maximum emission at 350 nm (Figure 
2-11). Such tunability would limit their use in multiplexing experiments where multiple 
fluorescent probes need to be employed. However, the fluorescence was generally weak and 
required a strong laser power for excitation which could be problematic during biomedical 
imaging in complex cellular matrix where difficulty in separating its signal from background 
cellular autofluorescence may be encountered. In particular, the red fluorescence (> 600 nm) 
is relatively faint making EGCNPs detection in biosystems challenging since most cell lines 
strongly auto-fluoresce in the blue and green regions.126 Hence, it is preferable for nano-
formulations to possess fluorescence in the red region (around and beyond 600 nm) for 
efficient tracking within cellular matrices.126 A strategy to enhance the fluorescent properties 
of EGCNPs to suit biomedical applications is discussed in Section 2.3.8.  
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Figure 2-10 Photoluminescent properties of EGCNPs. 
(a) Emission spectra showing peaks at 440nm, 533nm and 632 nm when excited with 390 nm, 450 nm, 
and 513 nm respectively, (b) corresponding excitation spectra with detection bandwidths set at 10 nm, 
(c) an EGCNPs suspension demonstrating strong blue to violet emission when excited with UV 
excitation source (380 nm), (d) EGCNPs powder showing broad green emission after blue light 
excitation. 
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Figure 2-11 EGCNPs maximum emission is blue shifted to 350 nm upon excitation with a wavelength 
of 270 nm. 
 
When examined with laser scanning confocal microscopy, emissions from EGCNPs dry 
powder could be detected across the blue, green and red regions using a single excitation 
wavelength (405 nm) as shown in Figure 2-12. This agrees with the broad emission spectra 
of EGCNPs upon UV excitation (Figure 2-10a).  
 
Figure 2-12 Confocal images of a cluster of EGCNPs powder upon 405 nm excitation with emissions 
detected at (a) 450 nm, (b) 550 nm and (c) 630 nm. 
 
The photoluminescent behaviour of nanoceria has been reported in the literature, but the 
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organophilic 2 – 3 nm oleic acid-coated CeO2 nanodots (OACNPs) fabricated by 
solvothermal decomposition.95 OACNPs dispersed in toluene exhibited blue (λex= 350), 
green (λex= 405) and red emissions (λex= 532).
95 These unique fluorescent properties were 
attributed to the quantum confinement effect due to the presence of a large number of crystal 
defects associated with the small nanoparticle size (2 nm) with a higher Ce3+ to Ce4+ ratio.95 
A CeO2 film deposited (80 nm) on a silica substrate was reported to have violet to blue 
luminescence at 380 nm.127  Nanoceria (2 nm), coated with a double layer of oleic acid 
prepared by thermal decomposition, were reported to have a broad spectrum with maximum 
emission at 515 nm with 400 nm excitation.128 As such, this is the first study to report that 
nanoceria prepared by an aqueous precipitation method can exhibit multi-coloured 
photoluminescence. Moreover, the ability to detect them with a fluorescent microscope in 
all visible regions of light spectrum using a single excitation wavelength is reported for the 
first time. 
2.3.7 EGCNPs colloidal stability and sterilisation 
After fully characterising EGCNPs, it was crucial to assess their suitability for use in 
physiologically relevant aqueous media before their use for in vitro studies. This should in 
turn develop an understanding of the role of the modified ethylene glycol coating in 
stabilising the nanoparticles. To achieve such purposes, dynamic light scattering (DLS), 
sedimentation over time, and sterilisation studies were carried out. DLS is a standard tool 
used to measure the hydrodynamic diameter and zeta potential of the nanoparticles in a given 
colloidal dispersion. The nanoparticles in a colloidal system undergo a Brownian motion by 
interacting with each other (inter-particular collisions) and with the solvent molecules. When 
light is shone on the nanoparticles, the light is scattered and the intensity of the scattered 
light that hit the detector will fluctuate due to the constructive and destructive interferences 
of the scattered light. By plotting the intensity fluctuations as a function of time (in 
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microseconds), an autocorrelation function (ACF) can be calculated from which the 
translational diffusion coefficient (Dt) can be measured from the decay rate of the ACF curve. 
Smaller nanoparticles have faster Brownian motion and hence loss of correlation in intensity 
fluctuations is faster. The translation diffusion coefficient (Dt) can then be used to calculate 
the hydrodynamic diameter using Stokes-Einstein equation:129  
𝐷𝑡 =
𝑇𝐾𝐵
6𝜋𝜇𝑅𝐻
 
 
Where T is temperature, KB is the Boltzmann constant, µ is viscosity, and RH is the 
hydrodynamic radius.  
Similarly, the zeta potential of the particles can be measured using DLS by applying an 
electric field to the dispersed nanoparticles and calculating their electrophoretic mobility. 
During electrophoresis, the moving nanoparticles scatter light with a frequency different to 
that of the original incident light. The shift in the frequency is dependent on the speed of the 
nanoparticles and is called Doppler shift. The scattered beam is compared to a reference 
beam from which the Doppler shift is measured. The velocity of the nanoparticles is then 
inferred using the Doppler shift value and the zeta potential  is measured by applying 
multiple mathematical equations.129 Together, the hydrodynamic diameter and zeta potential 
provide information on the stability of the nanoparticles in dispersions. 
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The intensity weighted mean hydrodynamic diameter (Z-average), polydispersity index (PDI) 
and zeta potential of EGCNPs were measured in three different aqueous media: water, 
EMEM supplemented with FBS (20%) and saline (0.9%). EMEM was used since it is one 
of the most commonly used cell culture media and will be the main media employed in the 
following chapters. The data are summarised in Table 2-1. 
Table 2-1 Particle size, polydispersity index and zeta potential measurements of EGCNPs in different 
physiological media (pH = 7, 25°֯C) 
 Media Z-average (nm) PDI Zeta (mV) 
1- Distilled Water 21.8 ± 0.6 0.28 + 44.1 
2- EMEM + FBS (20%) 128.7 ± 9.2 0.17 -  9.7 
3- 0.9% saline 158.1 ± 20.6 0.24 + 14.0 
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In all tested media, EGCNPs showed unimodal distribution of mean hydrodynamic 
diameters and no aggregation peaks were observed (Figure 2-13). On the other hand, a non-
coated nanoceria formulation showed an aggregation peak in water (>1000 nm) and the 
hydrodynamic diameter of the main peak was significantly larger at 133 nm (Figure 2-14) 
 
 
Figure 2-13 Distribution of the intensity-weighted hydrodynamic diameters (Z-average) of EGCNPs 
in different aqueous media.  
The histograms show unimodal distribution of EGCNPs in all media without signs of aggregation. 
 
 
Figure 2-14 The hydrodynamic diameter (Z-average) of non-coated cerium oxide nanoparticles in 
water showing polydispersity and aggregation. 
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The hydrodynamic diameter of EGCNPs was the smallest in water (21.86 nm) and increased 
significantly in other media while maintaining monodispersity. This was demonstrated by 
small PDI values (Table 2-1). The hydrodynamic diameter measured by DLS is expected to 
be inherently different from the particle size measured by TEM since the former is based on 
light scattering of the coating and hydration layer surrounding the particles while the latter 
is more sensitive to the core size of the particles.95  The increase in the hydrodynamic 
diameter in serum-containing EMEM is caused by the adsorption of a layer of serum proteins 
on the surface of nanoparticles forming a corona that contributed to its overall measured 
hydrodynamic diameter.130,131 The association of surface proteins was further reflected in 
the zeta potential value of EGCNPs and its inversion to a negative value.132 Serum proteins 
are predominantly negatively charged at physiological pH and hence their accumulation on 
the surface of the nanoparticles alters their zeta potential.133 In saline solution, the increase 
in the hydrodynamic diameter was expected as high salt concentrations are known to shield 
the electrical field around nanoparticles reducing the electrostatic repulsion and causing 
agglomeration.134 This is clearly manifested in the decrease in positive charge in saline 
solution compared to the value in water (Table 2-1). Despite that, the nanoparticles remained 
well dispersed in all media with no signs of precipitation or aggregation.  
Since nanoparticles must be sterile for biomedical applications, the small particle size in 
water permitted easy sterilisation by filtration through 0.22 µm syringe filters with minimal 
loss of the nanoparticles (less than 6% loss) as confirmed spectrophotometrically at 300 nm. 
The amount of EGCNPs lost after sterilisation was found to decrease as the volume of 
filtered solution passing through the same filter increased, suggesting that the loss was due 
to adsorption on the filter surface. This helped in avoiding high temperatures in autoclaving 
which may affect the stability of the nanoparticles. 
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When left to precipitate over one week at room temperature in water, EGCNPs showed a 
slight loss in the supernatant concentration (6%) over the testing duration. This level of 
stability was superior to their non-coated counterparts for which a significant loss in 
supernatant concentration (>35%) was observed after 24 h, highlighting the role of ethylene 
glycol coating in stabilising the dispersion (Figure 2-15).  The previously reported synthesis 
of ethylene-glycol coated nanoparticles was initiated from a nitrate precursor that resulted 
in hydrodynamic diameters of 222 nm and 206 nm in water and RPMI + FBS (10%) 
respectively, and both exhibited significant polydispersity with bimodal size distribution 
deeming them unsuitable for biomedical applications.113 Moreover, the colloidal stability 
study of that formulation showed substantial loss of nanoceria content in the supernatant 
where 38% were precipitated when a dispersion was left to precipitate over 7 days. Hence, 
it is shown that by simply synthesising nanoceria from a different precursor (an acetate 
precursor rather than a nitrate precursor), a noticeable enhancement on the stability of the 
nanoparticles with ethylene glycol can be achieved. This is attributed to the fact that the extra 
acetate ligands provided in the reaction mixture reacted with ethylene glycol and formed 
monoacetate and diacetate ethylene glycol derivatives as previously shown in  
Figure 2-7. These modified acetylated ligands are speculated to have provided improved 
stability via two proposed mechanisms. Firstly, the acetate ligands are longer and hence 
provided better steric hindrance stability by shielding the inter-particular attractive forces 
which in turn prevented aggregation.134 Secondly, the acetate derivatives provided the 
coating with additional polar carbonyl groups (C=O) that can form hydrogen bonding in 
aqueous solvents. It is also noteworthy the zeta potential plays an important role in stabilising 
the nanoparticles in aqueous media through electrostatic repulsion and usually a balance 
between steric hindrance and electrostatic forces has to be struck for optimum stability. To 
the best of the author’s knowledge, the EGCNPs described here are the simplest aqueously 
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stable nanoceria with a well-defined colloidal stability that can be formulated and stored in 
dry powder form. 
 
Figure 2-15 Colloidal stability of ethylene glycol-coated nanoceria (EGCNPs) and non-coated 
nanoceria kept in water at room temperature for a week.  
Concentration of nanoceria in the supernatant was determined at one-day intervals 
spectrophotometrically at 300 nm. 
 
2.3.8 Europium doping to enhance the photoluminescent properties of 
EGCNPs 
Although EGCNPs showed fluorescent properties as discussed in Section 2.3.6, the 
fluorescence was weak which therefore required further enhancement if the nanoparticles 
were to be employed in studies where fluorescence imaging in complex biological matrices 
(i.e. cellular monolayers or tissues) is needed. The nanoparticles were synthesised in a 
similar fashion, where europium ions (Eu3+) were doped inside the crystal lattice of cerium 
oxide, and the resultant nanoparticles are referred to as europium doped nanoceria (EuCNPs). 
Europium (Eu) is a rare earth lanthanide which produces a strong red fluorescence when 
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doped in different crystals.116 Doping with europium was chosen over the traditional 
attachment of fluorescent tags on the surface of the nanoparticles for several reasons. Firstly, 
minimal changes to the surface chemistry are induced by doping which is needed for 
maintaining the biomedical activity of the nanoparticles. Secondly, the bulk size of the 
nanoparticles remains unchanged.116  Thirdly, lanthanides such as europium have long 
fluorescence decay times enabling time resolved fluorometry and are resistant to 
photobleaching.126 Finally, the red emission of europium can be obtained when excited with 
different wavelengths extending from UV to visible light.116  
The synthesis of europium doped nanoceria has been previously reported and was shown to 
enhance the red fluorescence of nanoceria although their use in tracking nanoceria within in 
vitro cell lines was not reported in the literature.116 EuCNPs were characterised as before for 
EGCNPs and the main data are summarised in Figure 2-16. EuCNPs showed very similar 
particle size to EGCNPs (4.3 ± 0.8 nm). XRD data revealed the main diffraction peaks 
pertinent to the cubic fluorite structure of CeO2 crystal. No additional peaks specific to 
europium oxide were observed suggesting complete solubility of europium into the cerium 
oxide lattice. The main diffraction peaks of EuCNPs were slightly shifted to a lower 2θ angle 
compared to EGCNPs. This is caused by the slight expansion of the lattice parameters as a 
result of the higher ionic radius of Eu3+ ions (0.1066 nm) replacing the Ce4+ ions (ionic radius 
= 0.097 nm).116 This replacement leads to the creation of oxygen vacancies to compensate 
the loss in the positive charge maintaining the charge equilibrium.135 Importantly, EuCNPs 
exhibited typical strong red emission at 612 nm under multiple excitation wavelengths from 
UV to end of green region (ranging from 350 - 550 nm) rendering them suitable for 
biomedical imaging studies (Figure 2-16c and Figure 2-16d).116  
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Figure 2-16 Characterisation of europium-doped nanoceria (EuCNPs).  
(a) TEM image showing particles average size of 4 nm. (b) XRD analysis typical of nanoceria fcc 
crystal, (c) Excitation spectrum of EuCNPs with emission detected at 612 nm, multiple excitation 
wavelengths can be used to detect the particles at that particular emission wavelength, (d) Fluorescent 
microscope image of EuCNPs powder showing strong red fluorescence. The fluorescence was detected 
using RFP-compatible settings (excitation at 531 nm/40 nm, emission at 593 nm/40 nm) using a 
fluorescent microscope. 
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2.4 Conclusion 
A novel nanoceria formulation coated with ethylene glycol and ethylene glycol mono- and 
di- acetates (EGCNPs) was successfully formulated with an ultra-small particle size (4 nm) 
using a simple one-pot precipitation reaction starting from cerium acetate as a precursor 
under mild conditions. The modified synthesis has enabled the use of ethylene glycol as a 
coating material which was previously reported to induce significant polydispersity. This 
was not the case for EGCNPs as DLS and colloidal stability studies have shown that they 
possess superior aqueous stability and monodispersity in different physiologically relevant 
media paving the way for carrying out biological studies with no sedimentation-induced 
variabilities. Furthermore, EGCNPs exhibited multi-coloured photoluminescence which was 
observed for the first time for aqueously prepared nanoceria. Unfortunately, EGCNPs natural 
fluorescence was relatively weak requiring strong excitation for its detection. Therefore, a 
similar nanoceria formulation doped with europium (EuCNPs) was synthesised for 
employing in imaging studies.  
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3 Toxicity evaluation of EGCNPs in human lens 
epithelial cells 
3.1 Introduction 
The use and commercial applications of nanomaterials are rapidly booming in the 21st 
century. In 2015, it was estimated that nanomaterials global market was valued at 
approximately $14.7 billion and is projected to reach more than $55 billion by 2022 growing 
at compound annual growth rate of 20.7% during this period.136 Nanomaterials possess a 
very small particle size (usually between 1 - 100 nm in at least one external dimension), and 
a very large surface to volume ratio.137 This provides nanomaterials with unique physical, 
chemical, and biological characteristics that are different from those of the bulk form.138 The 
different characteristics and large surface area can result in a very high activity of the 
nanomaterials, which could also potentially lead to toxicity. Despite the exponential rise in 
the use of new nanomaterials, nanotoxicological evaluation is not carried out with a similarly 
high rate.138 Hence, assessing and evaluating the biocompatibility of nanomaterials are 
crucial issues for both the public and the scientific community to enable informed decisions 
regarding their use. 
Cerium oxide nanoparticles “nanoceria” are being researched for biomedical and drug 
delivery applications because of their unique regenerative antioxidant, neuroprotective, 
radioprotective and anti-inflammatory properties.81,88,97,99,139 Additionally, nanoceria are 
increasingly used for industrial applications as an additive to diesel fuel (commercially 
available under several trade names such as Envirox™) to reduce soot emissions and 
decrease fuel consumption.140,141 This has led to increased exposure to nanoceria which 
warrants investigation of their toxicological effects and interactions with various eukaryotic 
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cells. As such, nanoceria was considered a high priority for toxicological evaluation.141,142 
The toxicity of nanoceria has been studied in various in vivo and in vitro models.143 However, 
more  investigations into the mechanism of their action are needed.142 Additionally, many of 
the toxicological studies have been performed on nanoceria with unknown or poor colloidal 
stability, a common problem for nanoceria, which gives rise to conflicting toxicological 
profiles.  Although nanoceria are known for their powerful antioxidant properties, some 
studies have reported their ability to cause oxidative stress.142,144,145  Ocular exposure is of 
particular interest due to the ease for sustained environmental exposure. Although nanoceria 
have shown promise in treating some ocular diseases such as retinal degeneration,146 corneal 
inflammation,147 and glaucoma,148 there is a paucity of knowledge about toxicity of 
nanoceria in the lens.  
If nanoceria are to be used for the prevention and treatment of cataract, their safety to the 
human lens has to be evaluated. The human lens epithelial cell line (HLECs) provides a 
suitable model for studying the toxicity of nanoceria to the eye lens as these are the lenticular 
progenitor cells that differentiate into the lens fiber cells forming the bulk of the lens.149–151 
This transition is accompanied with distinct biochemical and morphological alterations such 
as the synthesis of lens fiber proteins (-crystallins and -crystallins), cell elongation and 
loss of cell organelles.149–151 Damage to the lens epithelium could disrupt protein expression, 
differentiation and could lead to aggregation of proteins that causes light scatter and 
manifests as cataract.149 
The aim of this chapter then was to (1) determine the concentrations of the well-characterised 
and colloidally stable EGCNPs formulation that can be safely used and tolerated in HLECs 
for short-term studies, and (2) explore the mechanism of acute toxicity of very high 
concentrations of EGCNPs in HLECs providing the first mechanistic investigation of 
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nanoceria toxicity in any ocular tissue. To achieve this, various cellular health indicators 
have been studied including growth rate, cellular morphology, cell membrane integrity, 
DNA integrity, mitochondrial morphology, mitochondrial membrane potential, ATP 
production and key apoptotic and necrotic hallmarks. 
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3.2 Materials and methods 
3.2.1 Cell culture and maintenance 
Human lens epithelial cells (HLECs) (B3, ATCC® CRL11421™, UK) were grown in 
Eagle’s minimum essential medium (EMEM, ATCC® 30-2003, UK) supplemented with 
foetal bovine serum (FBS, 20%, Scientific Laboratory Supplies), penicillin (100 IU/ml, 
Sigma Aldrich, UK) and streptomycin (0.1 mg/ml, Sigma Aldrich, UK). The cells were 
incubated at 37°C and 5% CO2 in a humidified environment. Sub-culturing (passaging) of 
the cells was carried out every three or four days by removing the growth media, washing 
once with Dulbecco's Phosphate Buffered Saline (D-PBS, 1X, ATCC® 30-2200™, UK) and 
incubating with trypsin/EDTA solution (0.025%, Lonza, UK) for 1 min at 37 °C. After 
detaching the cells, trypsin was deactivated by adding FBS-supplemented medium and 
passaging into new tissue culture flasks was performed using a sub-cultivation ratio of 1:3 
or 1:4. Cryopreservation of the cells was done using supplemented growth medium with 5% 
(v/v) dimethyl sulfoxide (DMSO, Fisher Scientific, UK) and the cells were stored in a liquid 
nitrogen vapour phase. For cell counting, of cell suspension (10 µl) was mixed with trypan 
blue solution (10 µl, 0.4%, Thermo Fisher, UK), and counting was performed using LUNA-
II™ Automated Cell Counter (Logos Biosystems, South Korea). The number of viable cells 
rather than total number of cells was used in all experiments. All experiments were 
conducted on cells in the logarithmic growth phase. 
3.2.2 Cell viability of HLECs after EGCNPs exposure (MTT assay) 
EGCNPs effect on HLECs viability was evaluated by MTT assay.152 HLECs were seeded in 
96-well plates with a seeding density of 5000 cells per well in 200 µl growth medium. The 
cells were left to recover from handling for 24 h before treatment. The medium was then 
gently aspirated and replaced with fresh medium containing different concentrations of 
EGCNPs. The tested EGCNPs concentrations were 0, 100, 200, 400, 600, 800, 1000 µg/ml 
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with four wells used per condition. After the treatment durations (24 h or 48 h), 20 µl of 3-
(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) solution (5 mg/ml 
in PBS, Sigma Aldrich, UK) were added to each well to reach a final concentration of 0.5 
mg/ml, and the cells were incubated at 37°C for 2 h. After incubation, the MTT solution was 
gently aspirated and DMSO (200 µl) were added to each well and left on a plate shaker for 
10 min protected from light to solubilise the formed formazan crystals. Absorbance readings 
were taken at 570 nm using a plate reader (Clariostar, BMG Labtech, Germany). EGCNPs 
were incubated with MTT solution in absence of the cells and no formazan crystals 
formation was observed. 
3.2.3 Proliferation of HLECs after EGCNPs exposure (live cell imaging) 
The effect of different EGCNPs concentrations on the proliferation and morphological 
features of HLECs was observed using real-time live cell analysis. HLECs were seeded in 
6-well plates with a seeding density of 1 x 105 cells per well in completed growth medium 
(5 ml) and immediately treated with different concentrations of EGCNPs (0, 50, 100, 200, 
400 µg/ml). The plates were imaged using the Incucyte® S3 Live Cell Analysis System 
(Essen BioScience, Germany) fitted inside an incubator set at 37 °C and 5% CO2. Four fields 
of view were imaged in each well every 3 h with 20x objective over 3 days. Confluence 
percentages were calculated using the integrated Incucyte® S3 software and growth curves 
were subsequently generated. 
3.2.4 Cell membrane integrity of HLECs after EGCNPs exposure (live cell 
imaging) 
The cell membrane integrity, a measure of cellular cytotoxicity, was evaluated in HLECs 
after exposure to different concentrations of EGCNPs (0, 50, 100, 200, 400 µg/ml) up to 72 
h by means of live cell imaging. This was conducted in the presence of Incucyte® Cytotox 
Red for counting dead cells (250 nM, Essen Bioscience, Germany), a cyanine nucleic acid 
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dye that only permeates cells with compromised cell membranes. Briefly, HLECs were 
seeded in 96-well plates with a seeding density of 5000 cells per well in completed growth 
media (200 µl) containing Cytotox Red and immediately treated with different 
concentrations of EGCNPs. Three fields of view were imaged in each well, with a 20x 
objective every 3 h over three days using the Incucyte® S3 Live Cell Analysis System fitted 
inside an incubator. The cytotoxicity level (cell membrane damage) was measured and 
expressed as the total fluorescent area of Cytotox Red (µm2) per image using the integrated 
Incucyte® software. 
3.2.5 Basal ROS level measurement (H2DCFDA assay) 
H2DCFDA probe (2',7'-dichlorodihydrofluorescein diacetate, D399, Thermo Fisher, UK) 
was employed to measure basal ROS levels as previously reported.153 Briefly, HLECs were 
seeded in 96-well plates in completed EMEM (5000 cells/well) and allowed to recover for 
24 h. The media was then removed and replaced with fresh medium containing different 
EGCNPs concentrations (0, 50, 100, 200 and 400 µg/ml) for 24 h. H2O2 (200 µM, Sigma 
Aldrich, UK) was used as a positive control. After the treatment period, the media was 
discarded, the cells were washed once with pre-warmed PBS (ATCC® 30-2200™) and 
incubated with H2DCFDA solution (10 µM in PBS) for 30 min at 37 °C. H2DCFDA solution 
was then discarded, cell washed with pre-warmed PBS and fresh PBS (200 μl) was added to 
each well. Dichlorofluorescein (DCF) fluorescence intensity was measured using a 
microplate reader (FLUOstar Omega, BMG Labtech, Germany) or a fluorescent microscope 
(EVOS FL, Thermo Fisher, UK) at excitation/emission of 485/520 nm. Correcting the 
fluorescence values was performed before data analysis by subtracting the fluorescence of 
unstained cells from all other values. No fluorescence was observed for cell-free 
H2DCFDA/PBS and H2DCFDA/PBS/ EGCNPs mixtures.  
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3.2.6 EGCNPs mitochondrial uptake and localisation (SEM-EDX) 
HLECs were grown in five T175 flasks until they were approximately 80% confluent. The 
cells were then treated with EGCNPs (400 µg/ml) for 24 h. The cells were then harvested, 
pelleted and washed once with full media and once with PBS. The mitochondria were then 
isolated from the pellet by means of differential centrifugation using the Mitochondria 
Isolation Kit for Cultured Cells (89874, Thermo Fisher, UK) in accordance with the 
supplier’s instructions. The isolated mitochondria were washed once with PBS, fixed with 
paraformaldehyde (4%, 5 min, Sigma Aldrich, UK) and dried in pure ethanol (5 min, Fisher 
Scientific). The mitochondria were then placed on an SEM aluminium stub covered with a 
carbon tape and the specimens were coated with a gold layer (5 nm) using a sputter coater 
(Q150R ES, Quorum, UK). The specimens were examined using a scanning electron 
microscope equipped with an EDX detector (JEOL, JSM-7100f, Japan). EDX spectra and 
mapping were acquired and processed using Aztec software (Oxford Instruments, UK). 
3.2.7 Mitochondrial morphology (confocal microscopy) 
HLECs were seeded (5000 cells/well) in black 96-well plates with clear flat bottoms 
(Falcon® 353219, Corning, USA) and left to establish for 24 h. The following day, the 
medium was discarded, and the cells were treated with EGCNPs-containing medium (0, 50, 
100, 200 and 400 µg/ml) for 24 h. H2O2 (200 µM) was used as a positive control. After the 
treatment period, the medium was removed, and the cells were washed once with pre-
warmed PBS. The cells were then incubated with full media containing MitoTracker™ Red 
CMXRos (200 nM, Thermo Fisher, UK) for 20 min at 37 °C. After staining, the cells were 
washed once with pre-warmed PBS, fixed in pre-warmed paraformaldehyde solution (4% in 
PBS) for 10 min at room temperature and permeabilised by incubating in ice-cold acetone 
(Fischer Scientific, UK) for 5 min. The cells were then counterstained by incubating in PBS 
containing Hoechst 33342 (2 μg/ml, Thermo Fisher, UK) and ActinGreen™ 488 
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ReadyProbes™ reagent (100 µl/ml) for 20 min at room temperature. Imaging was carried 
out using a laser scanning confocal microscope (Leica, Germany) using the following 
settings: sequential scanning, 20x dry objective, ex/em: Mitotracker: 543/599 nm, 
ActinGreen: 496/518 nm, Hoechst: 405⁄461 nm. 
3.2.8 Mitochondrial membrane potential (JC-1 staining) 
JC-1 probe (Abcam, UK) was employed for mitochondrial membrane potential 
measurements. HLECs were seeded (5000 cells/well), established and treated with different 
EGCNPs concentrations (0, 50, 100, 200 and 400 µg/ml) for 24 h. Sodium azide (1 and 2 
mM, Sigma Aldrich, UK) was used as a positive control. After the treatment period, the 
medium was removed, and cells were incubated with JC-1 probe in complete medium (10 
μM) for 30 min at 37 °֯C in dark conditions. The staining solution was removed, the cells 
were washed with PBS and replaced with phenol red-free complete medium. The wells were 
then imaged once using Incucyte® S3 high throughput imaging system using the green and 
red channels (5 wells per treatment condition, three images per each well) and quantification 
of the red/green ratio was calculated using the integrated software and the experiment was 
run in triplicate. Qualitative high magnification images were acquired using a laser scanning 
confocal microscope after nuclear staining with Hoechst 33342. The excitations/emission 
settings were as follows: Hoechst 33342 (405⁄461 nm), JC-1 green monomers (488/530 nm), 
JC-1 red aggregates (543/590 nm). 
3.2.9 ATP quantification (Luciferase assay) 
Quantification of cellular ATP was carried out using the luminescent luciferase assay 
(CellTiter-Glo, Promega, USA) in accordance with the supplier’s instructions. Briefly, 
HLECs were established in 96-well plates as before and treated with different EGCNPs 
concentrations for 24 h and 48 h. After the treatment period, the medium was removed and 
replaced with fresh medium. An equal volume of CellTiter-Glo reagent was added to each 
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well to lyse the cells and release a bioluminescent signal proportional to the amount of ATP 
present. The plate was placed on an orbital shaker for 2 min and then incubated in the dark 
at room temperature for 10 min to stabilise the signal. The luminescent signal was read using 
a luminometer (Infinite® 200 PRO, TECAN, Japan). 
3.2.10 Genotoxicity (immunocytochemistry) 
The DNA damage was evaluated using the HCS DNA kit (Thermo Fisher, UK) according 
to the supplier’s instructions. Briefly, HLECs were seeded in a black 96-well plate, 
established and treated for 24 h with different EGCNPs concentrations (0, 50, 100, 200 and 
400 µg/ml) as before. After the treatment period the medium was removed, the cells were 
fixed in paraformaldehyde solution (4%, 10 min), rinsed with PBS, and permeabilised in 0.2% 
Triton-X-100 (15 min). The cells were then washed with PBS and then incubated in a 
blocking buffer (1 %w/v bovine serum albumin in PBS, Melford, UK) for 1 h at room 
temperature. The blocking buffer was then removed, and the cells were incubated with the 
primary antibody solution (pH2AX mouse monoclonal antibody) for 1 h. The primary 
antibody solution was removed, and the cells were washed three times with PBS. The cells 
were then incubated with the secondary antibody/nuclear stain solution (Alexa Fluor 555 
goat anti-mouse IgG/Hoechst 33342) for 1 h. The secondary antibody solution was then 
removed, the cells were washed three times with PBS and replaced with fresh PBS before 
proceeding to imaging. Imaging was carried out using a laser scanning confocal microscope 
using the following settings: (sequential scanning ex/em: pH2AX: 543/565 nm, Hoechst: 
405⁄461 nm). For data analysis, Hoechst staining was used for nuclear segmentation and the 
DNA damage was measured by the increase in the fluorescence of pH2AX signal in the 
region defined as the nuclei. The experiment was repeated four times and at least 100 nuclei 
were analysed in each replicate. 
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3.2.11 Caspase-3,7 assay (live cell imaging) 
HLECs were seeded in 96-well plates (5000 cells per well) and left to establish for 24 h. The 
cells were then treated with different EGCNPs concentrations (0, 50, 100, 200 and 400 µg/ml) 
in supplemented EMEM in presence of IncuCyte® Caspase-3/7 Red Apoptosis Assay 
Reagent (0.5 µM, excitation/emission 630/650 nm). The cells were then imaged every 2 h 
for 24 h using the Incucyte® S3 live cell imaging system (Essen BioScience, Germany) fitted 
inside an incubator (5% CO2, 37 °C). Three fields of view were imaged per each well using 
a 20x objective. Images were then analysed, and the caspase activity was measured and 
expressed as the area of red fluorescent caspase signal (µm2) per image. The experiment was 
performed four times. 
3.2.12 Annexin V/Cytotox Red assay (live cell imaging)  
The assay was performed on the Incucyte® S3 live cell imaging system as mentioned in 
Section 3.2.11 but in the presence of double staining with IncuCyte® Annexin V Green 
Reagent /IncuCyte® Cytotox Red Reagent (250 nM). Excitation/emission maxima for 
Annexin V and Cytotox Red are 490/515 nm and 612/631 nm respectively. 
3.2.13 Statistical analysis 
Each experiment was conducted at least three times (n ≥ 3). Statistical analysis was carried 
out using GraphPad prism 7 software (USA). Where relevant, analysis of variance one-way 
or two-way ANOVA followed appropriate post-hoc test was used to compare groups with 
statistical significance set at p < 0.05. Details of statistical analysis are available in the figures’ 
legends.  Error bars are presented as means ± SEM. Asterisks were used to denote statistical 
significance with the following notation: (*) p ≤ 0.05, (**) p ≤ 0.01, (***) p ≤ 0.001 and 
(****) p ≤ 0.0001. 
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3.3 Results and discussion 
3.3.1 Effect of EGCNPs on cell viability, membrane integrity, proliferation and 
morphology of HLECs 
The impact of different concentrations of EGCNPs (0 to 1000 µg/ml) on the viability of 
HLECs, after 24 h and 48 h exposure in culture media was evaluated using the MTT assay 
and the data is shown in Figure 3-1.  
 
Figure 3-1 MTT reduction assay in HLECs with different EGCNPs concentrations.  
Concentrations up to 200 µg/ml are well tolerated by the cells after 48 hours of exposure. At 
concentrations of 400 µg/ml and beyond, significant decrease in viability was observed after treatment 
for 24 h. Error bars are presented as mean ± SEM. Asterisks denote statistically significant difference 
from the negative control, n = 3, one-way ANOVA, Dunnett’s multiple comparisons. Error bars are 
presented as mean ± SEM. 
 
EGCNPs concentrations up to 200 µg/ml did not have any significant effect on cell viability, 
when compared to control cells at the two tested time points (p value < 0.05). However, the 
24 h exposure to concentrations of 400 µg/ml and beyond resulted in a statistically 
significant decrease ranging from 27% (at 400 µg/ml) to 40% (1000 µg/ml). This is the first 
time to show the MTT cytotoxicity of any nanoceria formulation in HLECs and hence direct 
comparisons between EGCNPs and other nanoceria formulations are not feasible. However, 
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it is helpful to shed light on the cytotoxicity profile of similar nanoceria formulations 
employed in vitro in other mammalian cell lines. Previous studies have shown no 
cytotoxicity or anti-proliferative effect of a negatively charged ethylene glycol-coated 
nanoceria formulation (11 nm) on Jurkat human T-lymphocytes after three days of exposure 
to a concentration of 200 µg/ml.113 However, no uptake studies were conducted and hence 
the lack of cytotoxicity might have been the result of a lack of uptake of the nanoparticles. 
This is a serious concern since poor or lack of internalisation of negatively charged nanoceria 
has been previously found in two normal cell lines; embryonic kidney cells and H9c2 cardiac 
myocytes.154 The same study showed significant cytotoxicity of positively charged 
nanoceria (1 mM, 172 µg/ml) on the same cell lines after 24 hour exposure signifying the 
critical role the surface charge plays in determining the toxicity profile.154 It is noteworthy 
that the positive charges on the surface of nanomaterials promote cellular adhesion and 
penetration owing to the ionic interactions with negatively charged cell surfaces and hence 
their cytotoxicity is generally expected to be more pronounced compared to negatively 
charged nanomaterials.155,156 It is possible that the adsorption of negatively charge coronae 
on the surface of EGCNPs (as discussed in Chapter 2, 2.3.7) reduced their toxicity by 
mitigating cell membrane damage normally associated with positive charged 
nanoparticles.157  
Furthermore, the proliferation of HLECs incubated with different EGCNPs concentrations 
(0 to 400 µg/ml) was observed for three days without medium change. As shown in Figure 
3-2, HLECs with different treatments were able to reach 100% confluence following a 
similar growth pattern to the negative control. Statistically non-significant variation in the 
early stages of growth were observed as the cellular growth pattern in the four fixed imaged 
areas in each well can slightly change from one well to another. Additionally, the presence 
of EGCNPs during Incucyte® phase contrast imaging generates some artefacts which can be 
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misidentified as cells by the Incucyte® confluence analysis algorithm causing slight 
exaggeration of the confluence values in the treated conditions. Nonetheless, careful visual 
examination of the generated images shows similar growth rates. One interesting finding 
was that the 400 µg/ml did not adversely affect the proliferation rate over the tested duration. 
This contrasted with the results from the MTT assay (Figure 3-1) that showed a decrease in 
viability for cells incubated with EGNCPs with concentrations of 400 µg/ml and beyond 
which warranted further toxicological evaluation. 
 
Figure 3-2 Effect of different EGCNPs concentrations on HLECs proliferation.  
Cells were imaged in 6-well plates at an interval of 3 hours for 3 days while growing in full growth 
media using IncuCyte S3 live cell imaging system. Four different spots were imaged in each well. 
%Confluence was analysed by the integrated IncuCyte software and plotted against elapsed time in 
hours. Confluence at 0 h indicates the cell density at the point of seeding.  All cells reached full 
confluence by 72 h. Small variations in early stage of growth arise from statistically insignificant 
variations in the four areas imaged in each well.  
 
The cytotoxicity of EGCNPs in HLECs was further studied over 72 h by means of live cell 
imaging employing the Incucyte® Cytotox Red reagent. Cytotox Red is a cell-impermeable 
cyanine nucleic acid dye that is non-perturbing to the growth and morphology of growing 
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cells and has very little of any intrinsic fluorescence.158 Once the cells die, their cell 
membrane integrity becomes compromised enabling the dye to enter the cells and intercalate 
with DNA which is accompanied by 100 - 1000-fold increase in its fluorescence. This allows 
real-time analysis of cell death in response to various pharmacological agents including 
EGCNPs the subject of study in this work. As shown in Figure 3-3, no significant cytotoxic 
effect was observed for EGCNPs concentrations ranging from 50 - 400 µg/ml (compared to 
negative control) for an exposure duration up to 72 h. The cells maintained similar 
morphology without significant changes at all the tested concentrations and time points 
(Figure 3-3). At an EGCNPs concentration of 400 µg/ml, the Cytotox Red results were also 
in contrast with the MTT assay results. The conflicting data (between MTT and Cytotox Red 
assays at 400 µg/ml) suggested that at a concentration of 400 µg/ml, there seemed to be a 
toxic effect of EGCNPs in HLECs that did not manifest itself in the short-term proliferation 
and cell membrane integrity studies. Since the MTT assay is strongly associated with the 
mitochondrial activity where mitochondrial dehydrogenases in metabolically active cells 
reduce the yellow MTT tetrazolium salt to purple formazan crystals,159 it was hypothesised 
that the higher concentration of EGCNPs (400 µg/ml) could be adversely interfering with 
the mitochondrial functions which in turn manifested itself in MTT assay rather than the 
proliferation and cytotoxicity assays. Therefore, detailed investigations of how EGCNPs 
may affect the mitochondria and other cell health indicators in HLECs were necessary. This 
was conducted by measuring the effect of EGCNPs (with concentrations ranging from 0 to 
400 µg/ml) on the basal reactive oxygen species (ROS) levels, mitochondrial morphology, 
mitochondrial uptake, mitochondrial membrane potential, ATP levels, DNA damage, and 
apoptotic hallmarks. The results of these investigations are further discussed in the following 
sections. 
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Figure 3-3 Live cell analysis showing cytotoxicity, morphology and proliferation in HLECs upon 
EGCNPs exposure up to 72 h. No statistically significant cytotoxicity difference (One-way ANOVA) 
was found between different concentration at each time point.  
HLECs were treated with different EGCNPs concentration allowed to proliferate in presence of 
Cytotox Red dye (250 nM) that binds to the DNA of dead cells and gives red fluorescence. Images 
were taken using Incucyte S3 live cell imaging system (10x objective). (a) Control cells, (b) treated 
with 100 µg/ml EGCNPs, (c) treated with 200 µg/ml EGCNPs, (d) treated with 400 µg/ml EGCNPs. 
Error bars are displayed as mean ± SEM. No statistically significant difference found between treated 
and control cells at each time point (one-way ANOVA) indicating that EGCNPs are not cytotoxic at 
these exposure conditions. 
(a) 
(b) 
(c) 
(d) 
Day 1 Day 2 Day 3 
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3.3.2 Acute exposure to high EGCNPs concentrations increases basal ROS 
Overproduction of ROS is one of the most common pathways involved in nanomaterials 
toxicity.138 ROS are involved in the aetiology and pathogenesis of many diseases and 
disorders such as; Alzheimer’s disease, Parkinson’s disease, diabetes and cataract and hence 
the identification of the effects of new drugs on the redox state of a target cell line/tissue is 
essential.106,107,160,161 Therefore, the basal ROS level in HLECs was measured after 24 h 
exposure to different EGCNPs concentrations (0 - 400 µg/ml) using H2DCFDA probe. 
H2DCFDA is a non-fluorescent cell-permeable dye which is cellularly retained upon 
internalisation due to deacetylation, and then oxidised by the action of ROS into highly 
fluorescent DCF enabling relative estimation of ROS levels. As shown in Figure 3-4, 
EGCNPs concentrations up to 200 µg/ml did not lead to significant alteration to the basal 
ROS level when compared to control cells (p>0.05). This agrees with the aforementioned 
cell viability and cytotoxicity results. Conversely, when the EGCNPs concentration was 
increased to 400 µg/ml, a significant elevation in ROS level was observed indicating 
oxidative action exerted by EGCNPs agreeing with MTT assay results shown in Figure 3-1. 
This shows that even though EGCNPs possess antioxidant and ROS scavenging properties,81 
short-term overexposure to high concentrations can elevate ROS levels. This increase in 
ROS levels is likely to have been caused by Fenton/Haber Weiss like reactions where 
reduced metal ions (e.g. Ce3+) react with cellular hydrogen peroxide (H2O2) producing 
hydroxyl radicals (HO•) that are highly toxic to biomolecules.162 It was previously shown in 
Chapter 2 that EGCNPs had surface trivalent cerium (Ce3+) and hence the progression of a 
Fenton-like reaction is expected to occur as reported in the literature according the following 
equations:163 
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Figure 3-4 Effect of EGCNPs (24 h exposure) on basal ROS level in HLECs employing H2DCFDA 
fluorescent probe. 
 Measurement carried out by (a) a plate reader, (b) a fluorescence microscope. Asterisks denote 
statistical significance from negative control (0 µg/ml), n ≥ 3, one-way ANOVA followed by Dunnett’s 
multiple comparisons test, *p < 0.05. Error bars are presented as mean ± SEM. 
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3.3.3 EGCNPs localise in the mitochondria 
Since the mitochondria are the main source of ROS generation,138 it was necessary to 
investigate if EGCNPs exert their impact on ROS levels through becoming localised in the 
mitochondria. To achieve that, EGCNPs-treated HLECs were harvested and their 
mitochondria were isolated from the cytosolic fraction by differential centrifugation using a 
standard mitochondria isolation procedure.164 The isolated mitochondria were then 
examined with a scanning electron microscope (SEM) and the presence of cerium was 
checked for using energy dispersive X-ray spectroscopy (EDX). EDX is a valuable tool 
enabling the identification of different elements based on their emitted characteristic X-rays 
after excitation with a high accelerating voltage electron beam.165 By using this technique, 
it was feasible to avoid surface functionalisation with fluorescent markers; a common 
practice in the literature to track the localisation of the nanoparticles which changes the 
surface properties and in turn could affect the uptake behaviour of nanoparticles.166  Figure 
3-5a shows an SEM micrograph of the isolated mitochondria and its associated cerium EDX 
map (the red regions are associated with high cerium characteristic X-ray emissions). The 
full elemental composition of the scanned map is displayed in Figure 3-5b and the Mα and 
Lα characteristic X-ray emission peaks for cerium were observed at 0.88 KeV and 4.83 KeV 
respectively. Furthermore, semi-quantitative EDX elemental analysis shows that cerium was 
the third most abundant element in the mitochondria following carbon and oxygen. These 
findings clearly confirm that significant and uptake localisation of EGCNPs in the 
mitochondria occurs within 24 h of treatment. The mitochondrial localisation of EGCNPs is 
likely caused by the strong positive charge that EGCNPs carry (+44 mV) making the 
negatively charged interior of the mitochondria an ideal target.106 This finding is interesting 
since it is known from the previous investigation in Chapter 2 that protein coronae is 
adsorbed on the surface of EGCNPs making them slightly negatively charged (-9.7 mV) in 
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cell culture media containing foetal bovine serum. Nonetheless, the coronae did not seem to 
prevent the nanoparticles from entering the mitochondria. The surface charge is known to 
play a significant role in subcellular localisation of nanoceria which affects both the toxicity 
and activity profile.154 For example, it has previously been shown that targeting nanoceria 
specifically to the mitochondria by surface functionalisation with the mitochondrial targeting 
cationic ligand triphenylphosphonium suppresses oxidative stress-induced neuronal death in 
mice.106 The findings reported herein indicate that this specific functionalisation is not 
required for mitochondrial uptake in HLECs. 
 
Figure 3-5 SEM-EDX analysis of isolated mitochondria. 
(a) SEM micrograph of the mitochondrial enriched fraction isolated from HLECs treated with EGCNPs 
(left) and its associated cerium EDX mapping (right), (b) EDX spectrum and semiquantitative full 
elemental analysis generated from EDX mapping of the mitochondria. The presence of gold (Au) is 
due to sample coating with gold. Scale bars = 50 µm. 
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3.3.4 Effect of EGCNPs on the mitochondrial network 
Following the confirmation of mitochondrial uptake of EGCNPs, the effect of such uptake 
on the morphology and network organisation of the mitochondria in HLECs was studied. 
Staining with the mitochondria-selective stain (MitoTracker™ Red CMXRos) was 
employed and the cells were examined with a confocal microscope. MitoTracker™ Red 
CMXRos is a cell permeant dye that specifically accumulates in active mitochondria and 
permanently binds to mitochondrial thiol groups of cysteine residues owing to presence of 
reactive chloromethyl group (CH2Cl) allowing its retention even after cell fixation.
167 As 
shown in Figure 3-6a, the mitochondria were uniform in shape and organisation when treated 
with EGCNPs concentrations of up to 400 µg/ml and showed no significant difference from 
control cells. The mitochondria were short and rod-shaped with organized localisation in the 
perinuclear region (Figure 3-6b). H2O2 used as a positive control caused significant 
mitochondrial aggregation and diffusion of the mitochondrial network (Figure 3-6). This 
suggested that at the higher concentration (400 µg/ml) the cells could be undergoing early 
stage apoptosis where the shape of the mitochondria is known to remain intact during the 
process.168,169 Consequently, some of the key apoptotic hallmarks were further investigated 
to examine this assumption and further assess the toxicological profile of EGCNPs in HLECs.   
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Figure 3-6 Confocal examination of mitochondria in HLECs. 
(a) Representative confocal images showing the effect of different EGCNPs concentrations (24 h 
exposure) on the mitochondrial morphology and organization (magenta) in HLECs. (b) High 
magnification confocal images of the mitochondria counterstained with cytoskeleton selective stain 
ActinGreen 488 (green) and Hoechst 33342 (blue). No changes from control were observed up to 
EGCNPs concentrations of 400 µg/ml. H2O2 (400 µM) was used as a positive control which shows 
significant aggregation of the mitochondria.  
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3.3.5 Effect of EGCNPs on the mitochondrial membrane potential (∆Ψm) 
The integrity of the mitochondrial membrane potential is one the most critical factors in 
assessing the function of the mitochondria and its depolarisation (loss of normal charge 
distribution on both sides of the membrane) is an indicator for early stage 
apoptosis.124,168,170,171 Mitochondrial membrane depolarisation and formation of 
mitochondrial membrane transition pores allow the release of mitochondrial intermembrane 
space enzymes (e.g. cytochrome c) that activate the caspase cascade initiating 
apoptosis.124,172 JC-1 dye was used to differentiate between healthy and depolarised 
mitochondria based on the change in the dye’s fluorescence. In healthy mitochondria, the 
cationic dye accumulates into the negatively charged interior of mitochondria where it forms 
J-aggregates shifting the fluorescence from green to red. Consequently, decreased red/green 
ratio is an indicator for mitochondrial membrane depolarisation.173 This ratio is highly 
accurate as it reports on changes in membrane potential regardless of the shape, size or 
density of mitochondria.173 As shown in Figure 3-7, EGCNPs concentrations up to 200 
µg/ml had no significant effect on the (∆Ψm). When the concentration was increased to 400 
µg/ml, significant decrease in red/green ratio (membrane depolarisation) was observed 
suggesting that early stage apoptosis was taking place. For comparison, two different 
concentrations of sodium azide (NaN3) were used as positive controls since NaN3 is known 
to induce mitochondrial depolarisation by blocking complex IV activity in the mitochondrial 
electron transport chain.173 Figure 3-8 shows representative images acquired from high 
throughput Incucyte® S3 imaging system which were used for quantification of JC-1 
red/green ratio.  
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Figure 3-7 Effect of EGCNPs concentrations on mitochondrial membrane potential (∆Ψm) measured 
using JC-1 staining.  
Decrease in red/green ratio indicates depolarisation of the mitochondrial membrane. (a) Quantification 
of red/green ratio from high throughput Incucyte® S3 fluorescent images, (b) Representative high 
magnification confocal microscopy images with JC-1 staining counterstained with Hoechst 33342 
(blue) showing significant increase in green/red ratio (depolarised ∆Ψm) at 400 µg/ml. Up to 200 
µg/ml, the red and green had a ratio close to 1 causing them to colocalise. NaN3 was used as a positive 
control as it is a known disruptor of (∆Ψm). Asterisks denote statistical significance from control (***p 
≤ 0.001 and ****p ≤ 0.0001), n = 3, one-way ANOVA, Dunnett’s multiple comparisons. Error bars are 
presented as mean ± SEM. 
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Figure 3-8 Representative Incucyte® S3 images used for the quantification of JC-1 red/green ratio in 
HLECs after treatment with different EGCNPs concentrations.  
Three fields of view were imaged in each well (in 96 well plates), at least four wells were used for each 
treatment condition. The experiment was independently repeated three times (36 images were 
quantified per each condition). 
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3.3.6 Effect of EGCNPs on ATP level (luciferase assay) 
The intracellular ATP production is considered a well-accepted differentiator between 
apoptotic and necrotic cell death.169,174 Apoptosis is an energy-driven process which requires 
ATP for its execution. The cells require ATP in order to initiate the controlled apoptotic cell 
death through various ATP-dependent steps such as caspase activation, nuclear condensation 
and apoptotic bodies formation.174  When the ATP level drops significantly, it is an 
indication of the termination of controlled cell death and necrosis starts to take over. The 
changes in intracellular ATP production upon exposure to different EGCNPs concentrations 
were measured based on the bioluminescence produced using the highly sensitive luciferin-
luciferase assay according to the following reaction:174,175  
 
As shown in Figure 3-9, no significant decline in ATP level was observed in HLECs treated 
with EGCNPs concentrations up to 200 µg/ml which agrees with the previous results. 
Interestingly, no changes in ATP level was observed at 400 µg/ml even though 
mitochondrial membrane depolarisation does take place at this concentration. The cells were 
then treated for a longer duration (48 h), and a significant decrease in ATP production was 
observed at 400 µg/ml (Figure 3-9). This can be attributed to the termination of apoptosis in 
some of the cells with concomitant ATP depletion which manifested itself in the longer 
treatment duration. Another interesting finding was the slight increase (significant at 100 
and 200 µg/ml) in ATP level at low EGCNPs concentrations after 24 h. One possible reason 
is that the uptake of EGCNPs may have proceeded through energy-dependent clathrin-
mediated and caveolae-mediated endocytic pathways, which have been reported as the main 
uptake mechanism of nanoceria in many mammalian cell lines.118,154,166 
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Figure 3-9 Effect of EGCNPs on ATP production in HLECs measured by luciferin-luciferase 
bioluminescent assay at 24 h and 48 h.  
Asterisks denote statistical significance from control, n=3, one-way ANOVA. Error bars are presented 
as mean ± SEM. 
3.3.7 Genotoxicity (pH2AX immunocytochemistry) 
DNA integrity is particularly important if EGCNPs are to be used for cataract treatment and 
prevention. The eye lens is in continual growth amassing new cell layers on top of the older 
ones.109  HLECs are the stem cells of the lens that are found just beneath the anterior lens 
capsule and they are the initiators of the lens growth. HLECs synthesise the lens proteins 
(about 35% of the lens weight) and differentiate into lens fibre cells forming the bulk of the 
eye lens.6,109 Consequently, DNA damage in HLECs could lead to impaired protein synthesis, 
impaired differentiation and disruption of protein organisation which could result in 
alteration in the lens refractive index, lens opacity and cataract formation.6,109,176 EGCNPs 
induced genotoxicity was evaluated by detecting DNA double strands breaks (DSBs). As a 
response to DSBs, the histone protein H2AX is phosphorylated (pH2AX) which can be 
detected and quantified with immunofluorescence.177 Figure 3-10 shows a summary of main 
steps followed in the quantification of genotoxicity level in HLECs.  
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The results show that EGCNPs had no significant genotoxic effect up a concentration of 200 
µg/ml (Figure 3-11). However, at 400 µg/ml significant genotoxicity was observed (Figure 
3-11). It was shown before that nanoceria coated with 3-phosphonopropionic acid had no 
adverse effects on DNA health when exposed to a concentration of 10 µg/ml for 24 h.109 It 
is demonstrated here that EGCNPs can be tolerated at a 20-fold higher concentration (200 
µg/ml) for same treatment duration. However, an overdose (400 µg/ml) caused significant 
DNA double strand breaks as shown in Figure 3-11 agreeing with the above results. DNA 
damage at high EGCNPs concentration is likely caused by increased ROS which attack the 
DNA causing double strand breaks.162 Additionally, it is possible that some nuclear uptake 
of EGCNPs took place promoting genotoxicity.145 Even though some nanoparticles have 
poor permeability into the nuclei, their entry into the nuclei is inevitable during mitosis 
where the nuclear membrane is broken as the cells prepare for division.178 As such, higher 
doses of EGCNPs will provide more chance for increased localisation and possibly 
 
Figure 3-10 Schematic representation of the steps employed for the quantification of DNA damage 
(genotoxicity) by the detection of phosphorylated histone variant H2AX. 
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aggregation into the nuclei. The uptake and localisation of nanoceria in HLECs will be 
discussed in the following chapter. 
 
Figure 3-11 Effect of EGCNPs on DNA damage in HLECs (24 h) measured by immunocytochemistry 
thorough detection and quantification of pH2AX mean intensity.  
(a) quantification of pH2AX fluorescence intensity (only pH2AX signal inside nuclei perimeters) 
within at least 500 individual nuclei obtained from 4 independent experiments. (b) representative 
confocal images and 3D surface plotting of relative pH2AX intensity (red). Asterisks denote statistical 
significance from control (****p ≤ 0.0001), one-way ANOVA, Dunnett’s multiple comparisons. Error 
bars are presented as mean ± SEM.  
3.3.8 Effect of EGCNPs on caspase-3,7 activity  
The previous results suggested that very high EGCNPs concentrations (≥ 400 µg/ml) may 
be causing apoptosis in HLECs after short-term exposure (24 h) and hence some of the main 
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indicators of apoptosis were investigated to confirm this inference.  Activation of caspases 
is a key indicator of cells irrevocably committing to apoptotic death.172 The activation of 
caspases 3 and 7 (effector caspases in mammals) in HLECs upon EGCNPs treatment was 
detected over 24 h by means of live cell imaging using the IncuCyte® Caspase-3/7 Red 
apoptosis assay reagent. The reagent consists of a red fluorophore (NucView™633) attached 
to an activated caspase recognition motif (DEVD). Upon binding with activated caspases, 
the motif is cleaved, and the fluorophore is liberated then intercalates with DNA giving red 
fluorescence proportional to caspase activity that can be quantified over time. Figure 3-12 
shows that EGCNPs do not result in significant caspase activation up to concentrations of 
200 µg/ml compared to control cells. Overexposure to EGCNPs (400 µg/ml) caused 
significant caspase activation as soon as 12 h from the treatment. This agrees with the JC-1 
data (Figure 3-7) where loss of membrane potential was observed only at 400 µg/ml. It is 
well known that mitochondrial membrane depolarisation results in the release of cytochrome 
c from the mitochondrial intermembrane space into the cytoplasm where it activates 
apoptotic protease activating factor 1 (Apaf-1).172 The cytochrome c-Apaf-1 complex binds 
to ATP (which was shown to be amply present at 400 µg/ml) forming a complex known as 
apoptosome.172 The apoptosome then activates caspase 9 (an initiator caspase in mammalian 
cells) which in turn activates caspase 3 and caspase 7 to execute the apoptotic process.172 It 
should be noted that there was a systematic increase in caspase activation for each EGCNPs 
concentration (including control) over time which can be attributed to normal controlled 
death as cells grow in a confined area.  
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Figure 3-12 (a) Effect of different EGCNPs concentrations on caspase-3,7 activity in HLECs. 
No significant caspase activation was observed up to 200 µg/ml. At 400 µg/ml, significant caspase 
activity was observed as soon as 12 h of treatment, (b) representative Incucyte® images used for 
measurement and quantification of caspase-3,7 activity in HLECs after treatment with different 
EGCNPs concentrations (0 - 400 µg/ml) for 24 h. Asterisks denote statistical significance from control 
in same time group (**p ≤ 0.01), n=4, two-way ANOVA. Error bars are presented as mean ± SEM.  
 
3.3.9 Annexin V/Cytotox Red assay 
To further confirm cell commitment to the apoptotic rather than the necrotic pathway, at an 
EGCNPs concentration of 400 µg/ml, the cells were double stained with annexin V 
 
 
 
 
50 µg/ml 100 µg/ml 
200 µg/ml 400 µg/ml 
Control 
(a) 
(b) 
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green/Cytotox Red and observed by means of live cell imaging using Incucyte® S3 live 
imaging system. The cell membrane of healthy cells can be characterised by asymmetrical 
distribution of the anionic phospholipid phosphatidylserine (PS) where it is restricted to the 
inner leaflet of the cell membrane.179,180 During apoptosis, the asymmetry is disturbed and 
PS is externalised to the outer leaflet of the cell membrane.179,180  The activation of caspases 
has been linked in the literature to this externalisation process which allows the recognition 
of apoptotic bodies by adjacent cells.168 Annexin V is a protein (36 KDa) that binds to 
externalised PS in presence of Ca2+  and hence can be used to identify apoptotic cells by 
using a fluorescently labelled annexin V.179 Apoptotic cells only show annexin V labelling 
(green) while late apoptotic or necrotic cells are double labelled with both annexin 
V/Cytotox Red. Figure 3-13a shows that the 400 µg/ml concentration caused a significant 
increase in cells labelled with annexin V, when compared to negative control after treatments 
durations of 6 h, 12 h and 24 h supporting the caspase-3,7 data. No significant change was 
observed in the number of necrotic cells (labelled with Cytotox Red) over the same treatment 
durations (Figure 3-13b). Together, these findings indicate that apoptosis is the main 
mechanism of cell death in HLECs upon short-term overexposure (≥ 400 µg/ml) to EGCNPs.  
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Figure 3-13 Annexin V/Cytotox Red assay comparing non-treated (0 µg/ml) and EGCNPs-treated (400 
µg/ml) HLECs over 24 h. 
(a) quantification of apoptotic cells that only show annexin V staining, (b) quantification of necrotic or 
late apoptotic cells that show Cytotox Red staining, (c) representative Incucyte images of Annexin V 
green/Cytotox Red staining in HLECs comparing control and EGCNPs treated cells (24 h). Treated 
cells showed marked increase in annexin V labelling (apoptotic cells) without increase in number of 
necrotic cells (Cytotox Red). Asterisks denote statistical significance from control at the same time 
point (*p ≤ 0.05 and **p ≤ 0.01), n=4, two-way ANOVA. Error bars are presented as mean ± SEM.  
 
The toxicity of nanoceria has been studied  in vitro using a range of  cell lines (reviewed in 
Gagnon and Fromm, 2015),143 but the data are not comparable given  the varying 
characteristics of nanoceria used  including the shape, size, colloidal stability, zeta potential, 
surface valence, surface functionality and the range of nanoceria fabrication methods. There 
are still inconsistencies in the literature regarding the mechanism of nanoceria toxicity.142 
Control 400 µg/ml 
(b) (a) 
(c) 
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The results of the present study show, in a dose-dependent manner, the toxicity mechanism 
of well characterized nanoceria (EGCNPs) in human lens epithelium. To conclude, when 
considering nanoceria toxicity, and given their redox active characteristics, emphasis must 
be on the evaluation of the mitochondrial functionality as an early indicator for cell health 
as it can reveal significant effects that can be easily overlooked in short-term proliferation 
and standard toxicological studies. 
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3.4 Conclusion 
EGCNPs toxicity in HLECs was evaluated by studying varying cellular health indicators. 
The results show that EGCNPs had no cytotoxic or genotoxic effects up to concentrations of 
200 µg/ml and hence can be safely used for biomedical applications below that threshold. 
At a higher dose (400 µg/ml), EGCNPs induced ROS generation which mediated cellular 
apoptosis. It was clearly demonstrated that the cell death was driven by the mitochondrial 
apoptotic pathway, wherein ROS-mediated mitochondrial membrane depolarisation is 
followed by DNA damage and caspase cascade activation. To date, this is the first report on 
the mechanism of nanoceria toxicity in lens cells. To conclude, when considering nanoceria 
toxicity, emphasis must be on the evaluation of mitochondrial functionality as an early 
indicator for cell health; often overlooked in short-term proliferation studies. 
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4 Uptake, localisation and anti-cataract properties 
of EGCNPs in human lens epithelium 
4.1 Introduction 
A major cause of chronic diseases that are exacerbated by ageing, are changes in protein 
structure that lead to malfunction of tissues, organs and ultimately, to the system. These are 
conditions such as diabetes, Alzheimer’s disease and cataract.161,181 The latter can occur as 
solely ocular, or as a secondary manifestation of a systemic condition.22 This presents the 
opportunity of using cataract as a model for investigating the causal factors of visual 
impairment and to gain insight into causal factors that underpin systemic protein-based 
diseases. Cataract is an opacification of the eye lens that prevents light from reaching the 
retina by either scattering or absorbing traversing rays. It is the leading cause of blindness 
worldwide with over 24 million cases in the United States reported in 2010 which is expected 
to double by 2050.182 Cataract is a multifactorial disease with oxidative stress considered to 
be one of the major factors contributing to its development.22,26,183–186 The human lens 
possesses natural defence mechanisms against reactive oxygen species (ROS) including the 
presence of reduced glutathione and antioxidant enzymes such as superoxide dismutase and 
catalase.186 With ageing, such defences weaken, rendering the cells prone to oxidative insult 
that can lead to post-translational modifications and aggregation of lens proteins (crystallins) 
eventually causing cataract.22,26,186 Human lens epithelial cells (HLECs) are the stem cells of 
the lens that differentiate into fibre cells forming the lens body. Oxidative stress induced 
damage to the lens epithelial cells would result in faulty protein synthesis and aggregation 
that eventually would cause lens opacity.6 As such the use of HLECs as an in-vitro model 
has become important to draw conclusion on cataract progression. Currently, surgical 
91 
 
extraction of the cataractous lenses and replacement by intraocular implants is the only 
approved treatment. This comes with limitations such as accessibility in the developing 
world and the associated perioperative and postoperative complications.1 Additionally, to 
date there is no single implant model that can replicate the image quality and the capacity to 
alter focus that the biological lens can.51  
In the previous two chapters, the effective synthesis of a novel nanoceria formulation 
(EGCNPs) was achieved and its safety has been established in HLECs. In this chapter, the 
aim of research described in this chapter is to study whether EGCNPs can enter HLECs at 
the established safe concentrations, and if such entry will provide anti-cataract actions. For 
the purpose of the discussion of this chapter, anti-cataract actions are defined as the general 
ability of a therapeutic to protect against oxidative stress, improve natural enzymatic defence 
system in HLECs, and block one of the most common post-translational modifications in the 
human lens namely glycation.  
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4.2 Materials and methods 
4.2.1 Time-dependent uptake of EGCNPs in HLECs (ICP-MS studies)  
The cellular uptake of EGCNPs over time was measured employing inductively-coupled 
plasma mass spectroscopy (ICP-MS). HLECs were seeded in 6-well plates in complete 
EMEM (50000 cell/well) and allowed to establish for 24 h. The medium was then removed 
and replaced with fresh medium containing EGCNPs (200 µg/ml). Different plates were 
used to test the following EGCNPs incubation times: 0 min, 15 min, 1 h, 2 h and 4 h. After 
the specific incubation period with EGCNPs, the medium was removed, and the cells were 
rinsed three times with PBS to remove any surface bound EGCNPs. The washed cells were 
harvested using 500 µL trypsin-EDTA (0.25%) and collected in 20 ml Falcon tubes (3 
tubes/replicates per each time point). The number of collected cells in each tube was counted 
using LUNA-II™ Automated Cell Counter (Logos Biosystems, South Korea). The cells in 
each tube were then digested by adding concentrated nitric acid (HNO3, 2 ml, 70%) to each 
tube and left for three days to ensure complete digestion of EGCNPs. After digestion, the 
solutions were diluted to a known volume (12 ml) using 1% HNO3 and the insoluble material 
were removed by means of filtration. The concentration of cerium ions in each solution was 
calculated using ICP-MS (PerkinElmer NexION 1000, USA). A cerium standard for ICP 
(TraceCERT®, 1000 ppm Ce in nitric acid, Sigma Aldrich, UK) was serially diluted in 1% 
HNO3 to make the following concentrations:1000, 500, 250, 125, 62.5, 31.25 ppb, and a 
calibration curve was subsequently generated (available in the appendix). For accurate 
determination of cerium content in the cells, the amount of cerium in each condition (tube) 
was normalised to the counted number of digested cells and the results were expressed as 
cerium amount (ng) per 10000 cells. 
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4.2.2 Mechanism of EGCNPs uptake in HLECs 
To determine if the uptake of EGCNPs in HLECs proceeds mainly by passive uptake 
mechanism or energy-dependent endocytosis, two ways of measuring endocytosis inhibition 
were employed. Briefly, HLECs were seeded in 6-well plates as above and treated with 
chemical endocytosis inhibitors NaN3 (10 mM, Sigma Aldrich, UK) and 2-deoxy-D-glucose 
(2-DOG, 50 mM, Sigma Aldrich, UK) for 30 min. After the treatment period, EGCNPs (200 
µg/ml) were added to the cells and left for 3 h. The cells were then rinsed with PBS, and 
digestion and ICP-MS analysis were carried out as mentioned above. In a separate set of 
experiments, endocytosis inhibition was carried out by incubating the cells with EGCNPs 
(200 µg/ml) for 4 h at 4 °C instead of using chemical endocytosis inhibitors. All experiments 
were run in triplicate (n=3).  
4.2.3 Localisation of EGCNPs and EuCNPs in HLECs (SEM-EDX studies)  
HLECs were grown to 70% confluence in full growth medium on cover slips in 6-well plates 
and then treated with EGCNPs (200 µg/ml) and incubated for one minute, 4 h and 24 h. After 
each treatment duration, the medium was aspirated, and the cell monolayers were washed 
with serum free medium followed by fixation in paraformaldehyde in PBS buffer (4%) for 
15 minutes. The cells were then washed three times with PBS and dehydrated in graded 
alcohol solutions (50%, 60%, 70%, 80%, 90% and 100% ethanol) for five minutes each. The 
specimens were coated with layer of gold (5 nm) using a sputter coater (Q150R ES, Quorum, 
UK) and visualised under SEM (JEOL, JSM-7100f, Japan) with accelerating voltage of 10 
kV and probe current of 10 mA. EDX spectra were collected in at least ten different cell 
compartments using Aztec software (Oxford Instruments, UK). A contrast-sensitive pseudo-
colour was applied to the SEM images using imageJ (National Institutes of Health, USA) . 
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4.2.4 Localisation of EGCNPs and EuCNPs in HLECs (confocal studies)  
HLECs were seeded in black 96-well plates with clear bottoms (Corning 353219, USA) and 
established for 24 h. The cells were then incubated with 200 µg/ml EGCNPs or EuCNPs for 
24 h, fixed with paraformaldehyde (4 %w/v, 10 min) then permeabilised with Triton™ X-
100 (0.2 %v/v, 10 min, Fisher Scientific, UK). The cells were counterstained with Hoechst 
33342 (2 µg/ml in PBS, 10 min, Thermo Fisher, UK), washed with PBS (1X) and visualised 
using a TCS SP5 confocal laser scanning microscope (Leica, Germany). Fluorescent signals 
from both the nanoparticles and the nuclear stain were collected sequentially at same focal 
plane using a 20x dry objective (numerical aperture = 0.4) and a pinhole size of 0.9 AU. For 
EGCNPs detection, the cellular autofluorescence was first photobleached using a high 
intensity laser power for 2 min, and EGCNPs were detected at (530-560 nm) using 488 nm 
excitation laser line. In the case of EuCNPs, their fluorescence signal was strong enough 
compared to cellular autofluorescence to be detected and the nanoparticles were viewed 
directly at 612 nm using 514 nm excitation laser line. 
4.2.5 Protective effect of EGCNPs against oxidative stress in HLECs 
The protective effect of EGCNPs on oxidative stress levels in HLECs after H2O2 exposure 
was investigated using 2',7'-dichlorodihydrofluorescein diacetate (H2DCFDA) staining 
(D399, Thermo Fisher, UK) according to the supplier’s instructions. Briefly, HLECs were 
seeded in 96-well plates, established for 24 h, then pre-treated with different EGCNPs 
concentrations (0, 50 and 100 µg/ml) for 24 h. After the treatment period, the medium was 
removed, and the cells were washed once with PBS and replaced with complete medium 
containing H2O2 (100 µM) for 1 h. After 1 h, the medium was removed, washed once with 
PBS and the cells were incubated in H2DCFDA solution (10 µM in PBS) for 30 min at 37 °C. 
The cells were washed with PBS and PBS (200 µl) was finally added to each well. DCF 
fluorescence intensity was measured using a plate reader (TECAN infinite 200 PRO, Japan) 
95 
 
at excitation 495 nm/emission 529 nm. The experiment was run in triplicate. For qualitative 
images, the experiment was repeated, and DCF fluorescence was imaged in FITC channel 
using a widefield epi-fluorescent microscope (EVOS FL, Thermo Fisher, UK). 
4.2.6 The effect of EGCNPs pre-treatment and co-treatment on HLECs 
viability and proliferation when exposed to oxidative stress (live cell 
imaging) 
HLECs proliferation in presence of oxidative insult induced by H2O2 was observed for three 
days under two conditions:  (1) pre-treatment: the cells were pre-treated with EGCNPs for 
24 h before addition of H2O2 (100 µM), and (2) co-treatment: the cells were simultaneously 
treated with EGCNPs and H2O2. Briefly, HLECs were seeded in 96-well plates as described 
above and left to establish for 24 h.  The cells were then pre-treated with medium containing 
EGCNPs with different concentrations; 50, 100 and 200 µg/ml for further 24 hours. After 
the treatment period, the media was aspirated, the cells were washed with PBS, and replaced 
with fresh medium containing H2O2 (100 µM). The proliferation of EGCNPs-treated and 
non-treated HLECs was then observed for three days using the Incucyte® S3 live cell 
imaging system as described previously. For co-treatment experiments, the same steps were 
repeated excluding the EGCNPs pre-treatment step: EGCNPs were simultaneously added 
with H2O2 after the cells were established. 
4.2.7 Catalase mimetic activity of EGCNPs in HLECs 
To determine if EGCNPs protect HLECs against oxidative stress by exerting catalase-like 
actions, the catalase inhibitor 3-amino-1,2,4-triazole (3-AT, Sigma Aldrich, UK) was 
employed as reported in the literature with modifications.100,187 HLECs were seeded in 
complete EMEM in 96-well plates (5000 cells/well) and allowed to recover for 24 h. The 
cells were then preincubated with medium containing EGCNPs (50 µg/ml) for 24 h. A 
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negative control (no treatments) and a positive control (3-AT only) were also used. After the 
treatment period, the medium was aspirated, and cells were washed once with PBS and 
incubated with the catalase inhibitor 3-AT (100 mM) for 24 h. After the treatment period, 
the medium was aspirated, the cells were washed once with PBS and the viability of the cells 
was determined using the MTT assay as described previously. Cell viability was expressed 
as % of negative control. The experiment was repeated in triplicate.  
4.2.8 Effect of EGCNPs on GSH/GSSG ratio 
The effect of EGCNPs on the ratio between reduced and oxidised glutathione (GSH/GSSG) 
in HLECs was determined using GSH/GSSG ratio detection assay kit (fluorometric green, 
ab138881, Abcam, UK) according the supplier’s instructions. HLECs were seeded in 6-well 
plates in complete EMEM with a seeding density of 50000 cells/well and left to establish for 
48 h in an incubator set at 37 °C and 5% CO2. The medium was then removed and replaced 
with fresh medium containing EGCNPs (50 µg/ml) and the cells were treated for 48 h. A 
negative control (medium alone) was used for comparison. After the treatment duration, the 
cells were washed with cold PBS, lysed in radioimmunoprecipitation (RIPA) lysing buffer 
(200 µl, Thermo Fisher, UK) and homogenised in the lysing buffer by tilting the plate back 
and forth. The cell lysates were then collected in 2 ml prelabelled Eppendorf tubes and 
centrifuged at 22000 g for 15 min at 4 °C to remove insoluble cell material. The clear 
supernatants were then collected and transferred to clean Eppendorf tubes kept on ice. Since 
the lysates may contain enzymes that can interfere with the analysis, deproteinisation of the 
samples was carried out by adding 40 µl of trichloroacetic acid (TCA, 100% (w/v), Sigma 
Aldrich, UK) to all the samples and incubating on ice for 5 min. The samples were then 
centrifuged at 12000 g for 5 min at 4 °C, and the supernatants were transferred to clean 
Eppendorf tubes. The samples were then neutralised by slowly adding NaHCO3 (120 µl, 
10%, Fisher Scientific) making sure the pH does not exceed 7 as GSH can be easily oxidised 
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at pH > 7. The samples were centrifuged again as before, and the deproteinised and 
neutralised lysates were collected in fresh Eppendorf tubes. To make a calibration curve, 
GSH standards were prepared by serially diluting a stock solution (10 µM) in the supplied 
assay buffer (Abcam, UK). To measure reduced GSH concentrations, GSH assay mixture 
(thiol green solution) (50 µl) was added to an equivalent volume of samples and GSH 
standards in 96-well plates and left to incubate in the dark at room temperature for 1 h. The 
fluorescence was then read at ex/em = 490/520 nm using a plate reader (TECAN infinite 200 
PRO, Japan). Similarly, total glutathione concentrations (GSH + GSSG) was measured but 
in this case GSSG was reduced first to GSH using the supplied GSSG probe (Abcam, UK). 
GSSG concentration was calculated by subtracting GSH concentration from total glutathione 
concentration and GSH/GSSG ratio could be determined for all the samples. Each individual 
sample and standard were assayed in duplicate and their fluorescence were first corrected by 
subtracting the blank florescence from it. The experiment was repeated five times (n = 5).  
4.2.9 Measuring Antiglycation properties of EGCNPs 
The ability of EGCNPs to prevent protein glycation was determined by measuring the 
distinctive fluorescence of advanced glycation end products (AGEs) as previously reported 
in the literature.42 Briefly, two solutions of bovine serum albumin (BSA, 10 mg/ml)  D-
glucose (10 mg/ml) were separately made in PBS (pH = 7). Sodium azide was added to each 
solution (0.02%) as a preservative. Equal volumes of BSA and glucose solution were mixed 
in 2 ml Eppendorf tubes with or without treatments. The treatments were as follows: 
EGCNPs (50, 100, and 200 µg/ml) and aminoguanidine as an anti-glycating agent (10 and 
20 mM). The samples were incubated for three days at 40 °C. After the incubation period, 
aliquots were taken from all samples (100 µl) and placed in the wells of F-bottom black 96-
well plates (Greiner). The fluorescence intensity of AGEs was measured at ex/em: 300-9 
nm/400-20 nm using a plate reader (TECAN infinite 200 PRO, Japan). The same steps were 
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repeated using α-crystallin (1 mg/ml) and glucose (5 mg/ml) to check for protection against 
glycation in a lens protein. All experiments were run in triplicate. 
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4.3 Results and discussion 
4.3.1 Time dependent uptake of EGCNPs in HLECs and its mechanism 
Studying the interactions between nanomaterials and biological systems is crucial in 
understanding how the nanomaterials affect system function, and in turn, serves as a basis 
for improving the design of the nanomaterials to achieve the desired purpose. Biological 
systems are complex in nature making it challenging to predict the behaviour of a certain 
material in any given system.118 Nano-systems present extra challenges caused by their 
multi-faceted properties (e.g. size, charge, and aggregation state) which can dramatically 
change their physicochemical properties and hence their uptake in and interactions with 
biosystems.118 For example, it was reported in various studies that nanoparticles (specifically 
larger ones) can cause cell membrane rupture and deformation based on how they are 
uptaken.188,189 Additionally, for a nanomaterial to work as drug delivery system, a 
therapeutic or a diagnostic agent, it has to be able to pass through the cell membranes without 
causing damage. Nanomaterials can be erroneously claimed to be safe based on toxicological 
studies that have not correlated them with their cellular uptake. The lack of toxicity may be 
simply due to the lack of uptake and hence it is of paramount importance to associate them. 
Therefore, studying the uptake of nanomaterials is an integral part of understanding their 
activity and toxicity profiles. 
In this work, EGCNPs uptake in HLECs was studied in a time-dependent manner. The 
amount of cerium oxide internalised by the cells was accurately measured using ICP-MS. 
Before the analysis, the number of cells in different conditions were counted before 
preparatory digestion for ICP-MS to ensure highly accurate representation of the results, and 
to negate any variability that can be caused by slightly different growth pattern in different 
wells or plates. The predetermined highest safe EGCNPs concentration (200 µg/ml, see 
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chapter 3 for toxicological studies) was used in these experiments to ensure the availability 
of the nanoparticles in the growth medium throughout the specified experiment time. As 
shown in Figure 4-1, EGCNPs were rapidly internalised by the cells within only 15 min of 
incubation (4.8 ng of cerium per 104 cells). The uptake thereafter was shown to be time-
dependent increasing to 8.9, 17 and 26.4 nanograms of cerium per 104 cells after 1 h, 2 h and 
4 h respectively.  
 
Figure 4-1 Time dependent uptake of EGCNPs in HLECs.  
HLECs were incubated with EGCNPs for 0 min, 15 min, 1 h, 2 h and 4 h and the level of internalised 
cerium in the cells was measured by ICP-MS. The experiments were run in triplicate for each time 
point and the data are expressed as mean ± standard deviation (SD).  
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To further understand the mechanism of EGCNPs uptake, the cells were incubated with 
EGCNPs under two different conditions intended to suppress the endocytic pathway. 
Endocytosis is a main cellular internalisation mechanism for macromolecules, nanoparticles 
and solutes where a given material is surrounded by a membrane-bound vesicle before being 
engulfed by the plasma membrane.118 Contrary to passive cellular pathway, endocytosis is 
an energy-dependent process for which ATP is needed to proceed.118,166 Endocytosis can 
also be subclassified into two key categories: phagocytosis (i.e. cell eating for large particles) 
and pinocytosis (i.e. cell drinking for liquids and solutes).118,166 After internalisation, 
molecules are transported to different cell compartments based on a multitude of factors such 
as charge, size, and interactions with other cellular macromolecules.166 The first condition 
was to inhibit endocytosis chemically using sodium azide (NaN3) and 2-deoxyglucose (2-
DOG)  before adding the nanoparticles. These two chemicals deplete the cellular ATP level 
blocking the energy-dependent process.190 The second condition was to incubate the cells at 
4 °C which causes the cell membrane to become more rigid blocking the endocytic 
process.166  As shown in Figure 4-2, significant inhibition of EGCNPs uptake was observed 
under the two conditions when compared to negative control (i.e. no endocytosis inhibition). 
These results clearly indicate that energy-dependent endocytosis is required for efficient 
uptake of EGCNPs in HLECs. The results may also explain the previous data (reported in 
chapter 3, Figure 3-9) where slight increase in ATP level in HLECs was observed in the 
presence of different safe concentrations of EGCNPs corroborating the hypothesis that 
endocytosis was the drive for such an increase. It is noteworthy to emphasise that EGCNPs 
are also internalised to some extent in the presence of endocytosis-inhibiting conditions 
(Figure 4-2) which may suggest that even though endocytosis is the main uptake mechanism, 
other mechanisms such passive uptake pathway may be in action. A similar observation was 
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reported for carbon nanotubes where their uptake in multiple cell lines (such as A549, HeLa 
and Jurkat cell lines) was not predominately dependent on a single pathway.189 
The results herein present the first reported elucidation of nanoceria’s time-dependent uptake 
and its mechanism in HLECs. Therefore, one can only contrast the results with the uptake 
behaviour of similar formulations tested in different cell lines. Asati et al. studied the uptake 
of polymer coated nanoceria (3-4 nm) carrying different surface charges in multiple cell lines 
(cardiac myocytes H9c2, human embryonic kidney HEK293, lung cancer A549 and breast 
cancer MCF-7).154 The results showed that positively charged nanoceria were efficiently 
internalised by all the tested cell lines after 3 h of incubation. However, negatively charged 
nanoceria were poorly uptaken by HEK293, and did not enter H9c2 and MCF-7 cell lines.154 
Confocal studies (which are semi-quantitative compared to ICP-MS) also showed that 
endocytosis was the main mechanism uptake.154 Since EGCNPs carry a strong positive 
charge, it is also likely that this plays a role in its strong uptake by HLECs. Nonetheless, the 
uptake behaviour of different formulations should be assessed on an individual basis for a 
given formulation in the cell line of interest given the multitude of the factors that can affect 
it. 
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Figure 4-2 EGCNPs uptake in HLECs is endocytosis-dependent. 
HLECs were treated with EGCNPs (200 µg/ml) for 4 h with or without endocytosis inhibition. Two 
different ways to inhibit endocytosis were used; chemical inhibition (NaN3 + 2-deoxy-glucose) or by 
incubating the cells at 4 °C. In both cases, significant inhibition of EGCNPs internalisation was 
observed indicating that endocytosis is the main uptake mechanism. Asterisks denote statistical 
significance (n=3, p<0.05, one-way ANOVA). Error bars are presented as means ± SD. 
 
4.3.2 Localisation of EGCNPs and EuCNPs in HLECs 
The  cellular localisation of nanoparticles plays an important role in their overall toxicity 
and activity.191 Many factors impact on the uptake of nanoparticles such as particle size, 
polydispersity, zeta potential and surface coating. Cerium is a lanthanide element that does 
not naturally occur in human cells. Therefore, it was feasible to observe the localisation of 
the nanoparticles employing a scanning electron microscope equipped with energy 
dispersive x-ray spectroscopy (SEM-EDX). EDX is an elemental analysis tool that enables 
the detection of characteristic x-ray energy emitted from different elements (e.g. cerium) 
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after excitation with an accelerated electron beam. By examining different cell 
compartments, the presence or absence of cerium oxide can be confirmed. 
Figure 4-3 shows control cells (Figure 4-3a) and the uptake and localisation of EGCNPs in 
HLECs after incubation for 4 h (Figure 4-3b) and 24 h (Figure 4-3c). EGCNPs entered the 
cells at significant levels for both tested time points  agreeing with ICP-MS results. The 
nanoparticles were heavily localised in the cytoplasm, mainly in perinuclear regions Figure 
4-3b and Figure 4-3c). This supports the results in the previous chapter where significant 
mitochondrial localisation was detected. Minimal amounts of EGCNPs have been detected 
in the nuclei as confirmed by EDX spectra. The amount of nanoceria that entered the nucleus 
was slightly higher in the 24 h incubation period but the majority of the nanoparticles were 
retained in the cytoplasm. The cellular compartments with the most EGCNPs localisation 
were very distinct in the SEM images owing to the atomic number contrast. Heavy elements 
(e.g. cerium, atomic number = 58) backscatter electron strongly compared to the lighter 
elements that make up most of biological specimens, and hence appear brighter in the SEM 
images.192 By virtue of this phenomenon, a contrast sensitive pseudo-colour was applied to 
all the SEM images highlighting EGCNPs-containing compartments with a green colour 
(Figure 4-3). To ensure that the detected EGNCPs were not originating from poorly washed 
out nanoparticles, an experiment was carried out by incubating the cells for less than 1 min 
with EGCNPs, washed and fixed as other treated conditions. Under such condition, EGCNPs 
could not be detected by EDX (Figure 4-3). Representative EDX spectra confirming the 
presence of EGCNPs are shown in Figure 4-4. 
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Figure 4-3 SEM images showing uptake and localisation of EGCNPs in HLECs at different time points. 
(a) 1 min incubation showing no uptake of EGCNPs, (b) EGCNPs uptake and localization after 4 h 
incubation, (c) EGCNPs uptake and localization after 24 h incubation. Strong uptake was detected at 4 
h and 24 h time points with heavy localisation around the nuclei as detected by EDX. Areas with most 
nanoceria localization are distinguished by brightness arising from atomic number contrast of cerium 
element (Ce atomic number = 58) and hence it produces more secondary and backscattered electrons. 
Contrast sensitive pseudocolour was applied simultaneously to the images highlighting nanoceria 
localisation as bright green. Scale bars = 10 µm. 
 
 
(b) (a) (c) 
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Figure 4-4 EDX analysis in HLECs compartments. 
(a) a sample spectrum from the cytoplasm (perinuclear region) showing significant uptake of cerium 
(Ce) that was autodetected. (b) a sample spectrum from the nucleus with no or negligible cerium, in 
this case cerium was not autodetected and was manually input for comparison. Silica (Si) is present in 
both samples because of mounting on glass cover slips. 
 
 
(a) 
(b) 
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For further validation of EGCNPs uptake and localisation obtained by SEM-EDX, confocal 
microscopy experiments were conducted. As shown in Figure 4-5, HLECs exhibited strong 
autofluorescence in the blue and green regions when excited with a 405 nm laser line.  
 
Figure 4-5 Confocal images showing autofluorescence of human lens epithelial cells. 
(a) blue emission and (b) green emission after excitation with 405 nm.    
 
This presented a challenge for detecting EGCNPs fluorescence since it was relatively weak 
as discussed in chapter 2. This means that in order to detect EGCNPs natural fluorescence a 
strong excitation wavelength must be used which leads to simultaneous increase in cellular 
autofluorescence that masks EGCNPs fluorescence. By taking advantage of the ability of the 
lanthanide elements (e.g. cerium) to resist photobleaching,126 it was possible to track 
EGCNPs inside HLECs. This was achieved by photobleaching the cellular autofluorescence 
using a strong laser power minimising its interference with EGCNPs signal. As shown in 
Figure 4-6a and Figure 4-6b, EGCNPs were confirmed to be mainly localised in the 
cytoplasm corroborating SEM-EDX data. To the knowledge of the author, this is the first 
time unlabelled pure nanoceria have been successfully tracked inside any cell line employing 
fluorescent studies. 
 
(a) (b) 
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Figure 4-6 Uptake and perinuclear localisation of unlabelled EGCNPs in HLECs.  
(a) low magnification and (b) high magnification confocal images showing cytoplasmic localisation of 
EGCNPs (green) in HLECs (excitation 488 nm/emission 530 nm). Hoechst 33342 (blue) was used for 
nuclear staining. A negative control image is available in the appendix. 
 
To avoid interference with cellular autofluorescence, it is preferable for the nanoparticles to 
possess emissions at wavelengths above 600 nm where cellular autofluorescence is 
significantly minimised.126 In order to achieve significant emission in the longer wavelength 
end of the visible spectrum, a nanoceria formulation doped with europium (EuCNPs) was 
prepared and subsequently employed in confocal imaging. As discussed in chapter 2, the 
doped nanoceria (EuCNPs) exhibited typical strong emission at 612 nm under multiple 
excitation wavelengths from UV to end of green region (ranging from 350 - 550 nm).116 
Additionally, similar particle size (5 nm) and surface charge (+34.49 mV) to EGCNPs were 
achieved. Doping with europium was chosen over attachment of traditional fluorescent dyes 
since the latter involves surface modifications that could affect the behaviour of the 
nanoparticles uptake.193 After 24 h incubation with HLECs, As shown in Figure 4-7a, 
EuCNPs were found in the cytoplasm mainly in the perinuclear region corroborating the 
previous data. Additionally, EuCNPs showed a similar localisation pattern to EGCNPs when 
(a)  (b)  
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examined by SEM-EDX (Figure 4-7b). Single point EDX elemental analysis showed the 
presence of both cerium and europium in the cytoplasm confirming the uptake of the 
europium doped nanoceria (Figure 4-7c). It is therefore concluded that SEM imaging 
coupled with EDX spectroscopy is a potentially reliable technique for studying uptake and 
localisation of nanoceria in lens epithelial cells. It provides the convenience of not having to 
label the nanoparticles post synthesis in order to confirm their uptake. Nonetheless, EuCNPs 
do not seem to alter the uptake and localisation behaviour in HLECs and hence can be 
employed in multiplexing and colocalisation studies where multiple fluorescent probes need 
to be used simultaneously. This is possible as EuCNPs exhibit a sufficient fluorescence 
signal that, contrary to pure nanoceria, can be reliably distinguished from cellular 
autofluorescence (Figure 4-7a).  
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Figure 4-7 Uptake and perinuclear localisation of EuCNPs in HLECs.  
(a) a confocal microscopy image showing cytoplasmic localisation of nanoceria doped with europium 
(EuCNPs)in HLECs, EuCNPs showed similar localisation pattern to EGCNPs, (b) A SEM image 
showing cytoplasmic localisation of EuCNPs (green areas), (c) EDX analysis of the cytoplasm showing 
the presence of Ce and Eu confirming the cytoplasmic localisation of EuCNPs in HLECs.  
 
It was reported in chapter 3 that EGCNPs localise in the mitochondria which was revealed 
in SEM-EDX studies.  To further confirm these results, the fluorescent properties of EuCNPs 
were employed in confocal microscopy studies where the mitochondria of HLECs were 
stained with the mitochondrial specific stain MitoTracker™ Red CMXRos. The 
colocalisation of the fluorescent signals from both EuCNPs and Mitotracker were 
subsequently studied to check for the presence of EuCNPs in the mitochondria. One issue 
was that both Mitotracker Red and EuCNPs possessed strong red emissions at 612 nm when 
excited using their maximum excitation wavelengths (579 nm and 508 nm respectively), and 
111 
 
hence it was not possible to separate their signal based on their emission. Fortunately, 
EuCNPs red emission can be acquired at different excitation wavelengths as previously 
reported in chapter 2. Therefore, the fluorescent signals of both compounds were 
distinguished by selectively exciting EuCNPs at 476 nm at which Mitotracker fluorescence 
is negated. As shown in Figure 4-8, EuCNPs colocalised with mitochondria which is shown 
in the merged image. This confirms previous SEM-EDX results and the suitability of 
europium doping to track nanoceria in fluorescence studies.  
 
Figure 4-8 Mitochondrial localisation of EuCNPs observed by confocal microscopy. 
HLECs were incubated with EuCNPs and co-labelled with Mitotracker. Both Mitotracker and EuCNPs 
emissions were detected in the red region (612 nm) using different excitation wavelengths (543 nm and 
476 nm respectively). Although Mitotracker emission is effectively in the red region, it was pseudo-
coloured with green colour to allow visualisation of the merge image. The orange colour in the merge 
image indicates the areas where both Mitotracker (green) and EuCNPs (red) colocalise. Nuclei (blue) 
were stained with Hoechst 33342. 
 
Since it is well known that the mitochondria are the dominant hub for ROS generation 
(approximately 90% of ROS generation),194 the results reported herein show great potential 
for nanoceria in the treatment of age-related including cataract. This will be explored further 
in the upcoming studies to evaluate nanoceria’s efficacy in protecting the human lens 
epithelium from ROS-mediated injury. 
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4.3.3 EGCNPs protect the normal proliferation of HLECs when exposed to 
oxidative stress 
After establishing the efficient entry of EGCNPs into HLECs, the next step was to study if 
they can provide protection against one of the main cataract inducers namely; oxidative 
stress. Oxidative environment in the lens can lead to colouration, protein insolubilisation, 
denaturation and crosslinking.26 Oxidative stress takes place when the production of 
oxidative species outweighs the ability of the cellular natural anti-oxidant system to 
neutralise or degrade them.195 In the mitochondria and as part of the electron transport chain 
for energy production, full four-electron reduction of molecular oxygen (O2) into water (H2O) 
takes place.195 However, partial reduction of oxygen can also take place producing free 
radicals and ROS such as H2O2, hydroxyl radicals, and superoxide.
195 The source of free 
radical and ROS can also be exogenous from diet, radiation, sun exposure, smoking, and air 
contaminants.195  
EGCNPs with predetermined safe concentrations (100 and 200 µg /ml) were tested for their 
ability to protect the proliferation of HLECs from oxidative damage induced by H2O2. Two 
experimental conditions were tested; co-treatment (cells were subjected to oxidative stress 
simultaneously with EGCNPs) and pre-treatment (cells were incubated with EGCNPs for 24 
h and then subjected to oxidative stress in nanoceria-free medium). The proliferation of the 
cells in both conditions was observed for three days by means of live cell imaging. In the 
co-treatment condition, the two tested concentrations of EGCNPs exhibited a noticeable 
protective effect against H2O2 compared to non-EGCNPs treated cells. This was manifested 
in higher proliferation rate of the cells over the tested duration. The higher concentration of 
EGCNPs did not seem to provide further protection compared to the lower concentration 
(Figure 4-9). The results indicate the EGCNPs can easily deactivate H2O2 in growth medium.  
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Figure 4-9 Live cell analysis of HLECs growth showing protective effect of EGCNPs against oxidative 
stress induced by H2O2. 
The cells were incubated with H2O2 (100 µM) with or without EGCNPs treatments (co-treatment) and 
allowed to proliferate for three days at 37 °C, 5% CO2. Images were taken every 2 h using the Incucyte® 
S3 system. EGCNPs-treated cells were able to reach full confluency within three days while the growth 
of non-treated cells (H2O2 only) was significantly inhibited by H2O2. 
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In the pre-incubation condition (Figure 4-10), the tested concentrations showed similar 
protection against H2O2. The protection level was slightly higher in the co-treatment 
condition compared to pre-treatment conditions. In the former condition EGCNPs may have 
had direct contact with H2O2 in medium allowing for more efficient hydrogen peroxide 
deactivation. It is also noteworthy that the concentration of H2O2 used was considerably 
higher compared to that routinely used in other studies.183,185,196  
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Figure 4-10 Live cell analysis of HLECs pre-treated with EGCNPs for 24 h then treated with H2O2 for 
72 h. 
(a) confluence quantification, (b) representative images at different time points under different 
conditions. Images were taken every 2 h using the Incucyte® S3 system. EGCNPs-treated cells were 
able to reach full confluency within three days while non-treated cells (H2O2 only) proliferation was 
significantly inhibited. Asterisks denote statistical significance (n=3, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 
0.001 and ****p ≤ 0.0001, one-way ANOVA). Error bars are presented as means ± SEM. 
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4.3.4 EGCNPs protect against oxidative stress (H2DCFDA staining) 
EGCNPs, with predetermined safe concentrations (50, 100 and 200 µg/ml), were tested for 
their ability to protect HLECs from oxidative damage induced by H2O2 using H2DCFDA 
staining. H2DCFDA is a non-fluorescent cell-permeable dye which is cellularly retained 
upon internalisation due to deacetylation, and then oxidised by the action of ROS into highly 
fluorescent DCF enabling relative estimation of ROS levels. As shown in Figure 4-11, the 
tested EGCNPs concentrations exhibited a significant protective effect compared to non-
EGCNPs treated cells demonstrated by the low fluorescence levels in cells pre-treated with 
EGCNPs. All of the tested concentrations showed a similar level of protection against H2O2-
induced oxidative stress. Such protective effects suggest that EGCNPs inside the HLECs can 
exert catalase-like activity where excess H2O2 was deactivated.
100 This mechanism will be 
investigated in the following study. 
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Figure 4-11 EGCNPs protect against H2O2-induced oxidative stress in human lens epithelial cells 
(H2DCFDA staining). 
HLECs were pre-treated with EGCNPs for 24 h, and then exposed to H2O2 (100 μM) for 1 h in 
EGCNPs-free medium. Oxidative stress levels were determined by measuring DCF fluorescence 
intensity using (a) a plate reader, (b) a fluorescence microscope. Asterisks denote statistical significance 
(n=3, *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 and ****p ≤ 0.0001, one-way ANOVA). Error bars are 
presented as means ± SEM. 
(2) 
(4) 
(a) 
(b) 
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4.3.5 Catalase-like activity of EGCNPs in HLECs 
Catalase is a naturally occurring enzyme in the human lens epithelium.185 This provides a 
natural defence mechanism against H2O2 breaking it down into water and oxygen. When the 
lens ages, depletion of catalases takes place which in turn increases the propensity of the 
lens to oxidative insult that can lead to protein post-translational modifications and cataract 
formation.185  It was reported that transfecting mice lenses with catalase targeted only to the 
mitochondria led to significant delay in age-related cataract progression.197 This provides an 
incredible opportunity for EGCNPs to act as a catalase mimetic for cataract prevention since 
they were shown to localise significantly in the mitochondria of HLECs as discussed in the 
previous results. 3-AT (Figure 4-12) is a well-known catalase blocker causing cellular 
accumulation of intracellular H2O2 and cellular death.
100 This anti-catalase activity has been 
shown to exacerbate various oxidative stress related conditions such as Alzheimer’s, 
inflammatory diseases and liver dysfunction in both in-vitro and in-vivo models.100,187,198 
Therefore, in this study 3-AT was employed to irreversibly block the catalase activity in 
HLECs and determine the ability of EGCNPs to replace the activity of the inhibited catalase. 
 
Figure 4-12 Chemical structure of the catalase inhibitor 3-amino-1,2,4-triazole (3-AT). 
 
First, the effect of two concentrations of 3-AT (100 and 200 mM) on the viability of HLECs 
was studied at two time points; 4 h and 24 h. As shown in Figure 4-13, no decrease in cell 
viability was observed after 4 h exposure to both concentrations. At 24 h, however, both 
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concentrations (100 and 200 mM) significantly decreased cell viability by 37% and 76% 
respectively. Since the lower 3-AT concentration (100 mM) provided a significant viability 
reduction after 24 h exposure (p < 0.0001), it was deemed suitable to use that concentration 
and exposure duration in studying the catalase mimetic activity of EGCNPs.   
 
Figure 4-13 Dose and time dependent effect of the catalase inhibitor 3-AT on HLECs viability 
measured by the MTT assay. 
Asterisks denote statistical significance from the negative control (two-way ANOVA followed by 
Tukey’s multiple comparisons test, n=3, ****p ≤ 0.0001). Error bars are presented as means ± SEM.  
 
In a subsequent experiment, HLECs were pre-treated with EGCNPs for 24 h before exposure 
to 3-AT. The results show that HLECs pre-treated with EGCNPs exerted a significant 
protection against the cytotoxic effect of catalase depletion induced by 3-AT manifested in 
the increase in viability by 14% for the EGCNPs treated cells (Figure 4-14). This indicated 
that EGCNPs can act as a nanozyme exhibiting catalase-like activity in HLECs making them 
a promising mitochondrial targeted anti-cataract therapy. This concurs with the previous 
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observations in the proliferation studies of HLECs where EGCNPs provided protection 
against the oxidative insult induced by H2O2.  
 
Figure 4-14 Catalase-mimtetic activity of EGCNPs in HLECs. EGCNPs protect against damage 
induced by the catalase inhibitor 3-AT (100 mM).  
The asterisk denotes statistical significance (n=3, p<0.05, Student’s t-test). Error bars are presented as 
means ± SEM.  
 
4.3.6 Effect of EGCNPs on GSH/GSSG ratio 
Glutathione (GSH) is a tripeptide (-glutamyl-cysteine-glycine) that plays an important role 
in the defence system of the human lens against oxidative stress-induced damage.29,186 The 
eye lens naturally contains a high concentration of glutathione in its reduced form (GSH) in 
addition to high content of thiol-containing proteins (protein-SH). The crosslinking between 
such proteins through the formation of disulphide linkages (protein-S-S-protein) is implied 
in cataract formation.186 The presence of reduced GSH in the eye lens protects the thiol 
content from such crosslinking maintaining the lens transparency through the oxidation of 
the reduced GSH to its oxidised form GSSG.186 GSH levels in the lens decrease with age 
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with a concomitant increase in disulphide glutathione GSSG.29 This is reported to be one of 
the most characteristic features of nuclear cataract formation.26,195 This loss is also observed 
in the majority of experimentally induced cataracts.26,199 Therefore, it was suggested that 
maintaining high levels of GSH in the eye lens can play an important role in the prevention 
of cataract formation. 
In this study, the effect of EGCNPs on GSH/GSSG ratio in HLECs was investigated after 
48 h exposure to the nanoparticles. This was achieved using a sensitive one-step fluorometric 
assay to quantify reduced GSH content and total glutathione content (GSH + GSSG) from 
which GSSG content was calculated. The assay employs a non-fluorescent probe that reacts 
with GSH emitting strong fluorescence that can be quantified using a spectrofluorometer. 
The total glutathione concentration was measured by enzymatically reducing GSSG to GSH 
and using the same probe for quantification. From a calibration curve plotted using GSH 
standards (Figure 4-15a), the content of GSH can be accurately calculated and compared 
across different samples. As shown in Figure 4-15b, HLECs treated with EGCNPs (50 µg/ml) 
showed significant improvement (p<0.05) of GSH/GSSG ratio compared to the negative 
control. 
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Figure 4-15 Effect of EGCNPs on GSH/GSSG ratio in HLECs. 
(a) GSH standards calibration curve (R2 is 0.9999) generated using a spectrofluorometer at ex/em = 
490/520 nm, (b) 48 h exposure to EGCNPs (50 µg/ml) significantly increase GSH/GSSG ratio 
compared to negative control. The asterisk denotes statistical significance (n=5, p<0.05, Student’s t-
test). Error bars are presented as means ± SEM.  
 
 
(a) 
(b) 
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As shown in Figure 4-16, the increase in GSH/GSSG ratio can be primarily attributed to 
increased content of GSH in EGCNPs-treated cells. Additionally, GSSG concentration in 
treated cells was slightly lower but non-significant compared to control cells. This finding 
is the first of its kind for showing the impact cerium oxide nanoparticles on GSH/GSSG in 
HLECs. It has been previously reported that cerium chloride loaded mesoporous silica 
(CeCl3@mSiO2) nanoparticles increase GSH content in diabetic rat lenses after eight weeks 
of exposure.200 This may suggest that cerium, as an element, may play a role in promoting 
the cellular synthesis of GSH which is worthy of further investigation. Together, these results 
indicate great potential for EGCNPs in cataract prevention not only because of their direct 
antioxidant properties but also for their GSH promoting effect. 
 
Figure 4-16 Effect of EGCNPs (50 µg/ml) on GSH and GSSG concentrations in HLECs after 48 h 
exposure.  
The asterisk denotes statistical significance (n=5, p<0.05, Student’s t-test). Error bars are presented as 
means ± SEM. 
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4.3.7 Effect of EGCNPs on protein glycation  
Protein glycation is one form protein post-translational modifications where sugars and 
proteins react non-enzymatically leading to the formation of advanced glycation end 
products (AGEs).201,202 The glycation process proceeds very slowly over a period of weeks 
through a series of  reactions between the amino groups of proteins and reducing sugars such 
as glucose.203 The reactions start with rapid formation of Schiff base adducts followed by 
slow Amadori rearrangement and finally AGEs formation in a complex process known as 
the Maillard reaction.202 This makes crystallins an ideal target for glycation due to the lack 
of protein turnover in the lens.22 The formation of AGEs were shown to be strongly 
implicated in many pathologies including Alzheimer’s, diabetes, retinopathy, nephropathy, 
atherosclerosis and cataract formation.22,202,204 Glycation of the lens proteins has been 
previously shown to induce protein conformational changes, crosslinking, yellowing and 
aggregation that are more pronounced with diabetes.22 In addition to the direct damage to 
crystallins, sugars can deactivate enzymes including the natural anti-oxidant defence system 
in the lens (e.g. catalase, superoxide dismutase, glutathione and glutathione reductase) which 
can lead to the build-up of oxidative stress; a major cause of cataract development.35 Since 
oxidative stress is also known to expedite and promote the glycation process, this creates a 
vicious cycle between AGEs and ROS. 
The ability of EGCNPs to prevent protein glycation was tested in-vitro by measuring the 
inhibitory effect of the nanoparticles on the formation AGEs of a model protein (BSA) when 
incubated with glucose. BSA was chosen for preliminary testing because of its low cost and 
the availability of previous glycation studies carried out on it in the literature.204 
Fluorescence studies were employed to measure AGEs formation owing to AGEs 
characteristic fluorescence.204 High fluorescence intensity of protein and sugar mixtures is 
usually indicative of higher degree of protein glycation.204,205 Three EGCNPs concentrations 
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(50, 100 and 200 µg/ml) were tested and the antiglycation effect was compared to two 
concentrations of the standard antiglycation agent aminoguanidine (10 and 20 mM). As 
shown in Figure 4-17, all of the tested EGCNPs concentrations showed highly significant 
inhibition of protein glycation (****p < 0.0001) when compared to the non-treated 
protein/glucose mixture.  
 
Figure 4-17 Effect of EGCNPs on the inhibition of the formation of advanced glycation end products 
(AGEs) for bovine serum albumin (BSA) when incubated with glucose (glu) for 72 h.  
For comparison, two concentrations of aminoguanidine (AG) were used as it is known for its 
antiglycation actions. AGEs formation was measured spectrofluorometrically using a plate reader at 
ex/em = 300/400 nm. Asterisks denote statistical significance from BSA + glu, (n=3, *p ≤ 0.05, **p ≤ 
0.01, ***p ≤ 0.001 and ****p ≤ 0.0001, one-way ANOVA). Error bars are presented as means ± SEM. 
 
The anti-glycating effect EGCNPs was concentration dependent with a decrease in AGEs 
formation by 13%, 24% and 33% at EGCNPs concentrations of 50, 100 and 200 µg/ml 
respectively. The percentage decrease in AGEs formation for aminoguanidine was 10% and 
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16% at 10 mM and 20 mM respectively. The results clearly demonstrate that EGCNPs can 
act as a potent anti-glycating agent. It is noteworthy that the glucose concentration employed 
in this study was significantly higher than the concentration that is naturally found in normal 
and diabetic lens (0.7–2.2 mM and 3–4.5 mM respectively).206  
Building on the previous results, it was necessary to investigate if EGCNPs could have 
similar anti-glycating effects on the eye lens proteins (i.e. crystallin). For that, bovine α-
crystallin was chosen for testing EGCNPs effects. Not only is α-crystallin one of the main 
structural lens proteins, but it also functions as a molecular chaperone that protects other lens 
proteins and enzymes from aggregation.35 In addition, α-crystallin is known to be among 
proteins prone to glycation in presence of sugars.207 It was shown that α-crystallin protects 
other proteins such as glutathione reductase and catalase against protein glycation over 
several days.35 Such protection was exerted regardless of the species of α-crystallin (bovine 
or human).208,209 Moreover, α-crystallin protects against protein inactivation caused by 
glucocorticoids, which are a known risk factor for cataract development.35,210 For example, 
bovine α-crystallin was reported to fully protect against catalase inactivation induced by six 
day incubation with prednisolone-21-hemisuccinate; a protective effect that was only 
specific to α-crystallin compared to other control proteins.211 For the aforementioned reasons, 
α-crystallin was chosen for studying EGCNPs anti-glycating effect. 
As shown in Figure 4-18, EGCNPs exhibited significant protective effects against the 
glycation of α-crystallin upon incubation with glucose for three days. This is shown to 
decrease AGEs fluorescence in all treated conditions compared to non-treated protein and 
glucose mixture (Figure 4-18). Similar to BSA glycation data, EGCNPs protected α-
crystallin in a concentration dependent manner where mean AGEs formation was decreased 
by 15%, 26% and 34% at EGCNPs concentrations of 50, 100 and 200 µg/ml respectively. 
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Aminoguanidine (AG) also decreased mean AGEs formation in α-crystallin by 5% and 7% 
respectively although, unlike the BSA data, the anti-glycating effect of the lower AG  
concentration was not statistically significant (p=0.09). This could be attributed to the higher 
glucose/crystallin ratio used compared to glucose/BSA ratio. Nonetheless, AG (20 mM) 
showed significant inhibition of AGEs formation. Importantly, all tested EGCNPs 
concentrations exhibited stronger anti-glycation actions compared to the highest AG 
concentration. It was previously shown that AG slows cataract formation in moderately 
diabetic rats (plasma glucose< 350 mg/dl), but its actions were overwhelmed in severely 
 
Figure 4-18 Effect of EGCNPs on the inhibition of the formation of advanced glycation end products 
(AGEs) for bovine α-crystallin when incubated with glucose (glu) for 72 h. 
For comparison, two concentrations of aminoguanidine (AG) were used as it is known for its 
antiglycation actions. AGEs formation was measured spectrofluorometrically using a plate reader at 
ex/em = 300/400 nm. Asterisks denote statistical significance from BSA + glu, (n=3, *p ≤ 0.05, **p ≤ 
0.01, ***p ≤ 0.001 and ****p ≤ 0.0001, one-way ANOVA). Error bars are presented as means ± SEM. 
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diabetic rats (plasma glucose< 350 mg/dl).212 It was also suggested that protection against 
glycation is not enough on its own to resist severe diabetes.195 The results from different 
reports in literature suggest that a drug possessing both antioxidant and anti-glycating 
activities would be more effective than a drug that possess only one of them.195,213 The data 
shown here suggest that EGCNPs may present a more preferable alternative given the 
nanoparticles’ additional beneficial protective effects. Together these results show that 
EGCNPs have potential in protecting against glucose-induced deactivation of one of the 
abundant crystallin classes. Preserving α-crystallin activity will in turn provide further 
protection of the other lens structural proteins and the lens antioxidant enzymes due its 
chaperone activity. The results also may predict that EGCNPs can protect against the 
glycation of other structural lens proteins (-crystallin and -crystallin) given their structural 
similarity.214 The mechanism by which cerium oxide nanoparticles prevent protein glycation 
could be ascribed to the activity of surface Ce3+ towards many functional groups such as the 
free amino groups (NH2) of α-crystallin that constitute the main targets of glycation.
201 
Another possible explanation is that the antioxidant capability of the nanoparticles helped to 
decrease glycation-promoting free radical in the protein/sugar mixtures. To the best 
knowledge of the author, this is the first report of cerium oxide nanoparticles (CeO2) 
possessing protective actions against glucose-induced α-crystallin glycation. 
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4.4 Conclusion 
In this chapter, the uptake mechanism and localisation of nanoceria (EGCNPs) have been 
elucidated for the first time in HLECs. It was demonstrated that safe concentrations of 
EGCNPs enter HLECs very quickly (as short as 15 min), and in a time-dependent manner. 
The uptake proceeded mainly through energy-dependent endocytosis. SEM-EDX and 
confocal studies have demonstrated that the nanoparticles localise primarily in the cytoplasm 
of the cells particularly in the mitochondria. This efficient entry of EGCNPs in HLECs 
allowed the nanoparticles to exert anticataract actions that were demonstrated in: (1) their 
ability to protect the cells against external oxidative stress manifested in normal proliferation 
and total ROS in treated cells, (2) their ability to replace the activity of the catalase enzyme, 
(3) improving the ratio between reduced and oxidised glutathione (GSH/GSSG), and finally 
(4) their ability to provide a significant protection against the glycation of lens proteins 
which is one of the major causes of cataract particularly in diabetics.  Given the multifactorial 
nature of cataract where no one single cause is solely responsible for its progression, 
EGCNPs demonstrated varied actions providing a highly promising alternative for non-
surgical intervention.  
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5 General discussion, conclusions and 
recommendations for future work  
5.1 Discussion and conclusions 
The work presented in this thesis provides new hope for finding an alternative for cataract 
surgery. To date, surgery is the only effective treatment for cataract, but it is costly, not easily 
accessible to patients particularly in the developing world and comes with perioperative and 
postoperative complications. The way to creating a new dawn for cataract treatment is 
contingent on finding therapeutics that can either delay, halt or reverse the disease process. 
Identifying a therapeutic intervention that is successful in reversing or preventing cataracts 
may have applications for other chronic diseases of protein misfolding, such as diabetes and 
Alzheimer's disease as these have similar causation factors, notably oxidative stress.161,181 
In this work, cerium oxide nanoparticles “nanoceria” were proposed as a potential anti-
cataract non-surgical treatment because of their inherent antioxidant, radioprotective, 
enzyme mimetic and recyclable properties. Given the cumulative evidence associating 
oxidative stress with cataract development and progression,26 testing if these nanoparticles 
have benefit for cataract seemed to be a logical and unexplored research direction. Although 
cataract is primarily age-related, the causes behind its development are multi-faceted. 
Therefore, the use of nanoparticles that can offer protection against multiple potential causes 
is an attractive strategy for cataract treatment. Many conventional antioxidants such as 
vitamin C, vitamin E and L-carnosine have shown potential for cataract prevention, but the 
proposed cerium oxide nanoparticles are superior to these compounds for two main reasons. 
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Firstly, cerium oxide can deactivate free radicals without being transformed into a free 
radical itself.81 Secondly, the particles can recycle themselves in an ambient environment 
regenerating their antioxidant properties in the process.81 The latter is a very attractive 
attribute for chronic diseases since it can significantly decrease dosage frequency and 
increase patient compliance. The use of nanotechnology offers additional advantages as well 
in terms of the ability to enhance and optimise drug penetration, release, targeting and the 
ability to combine multiple therapeutics in a single entity.215 
The start of this project aimed to formulate cerium oxide nanoparticles with several concerns 
in mind before proceeding to biological testing. These were:  
1- The particle size should be very small preferably below 5 nm. This was needed to 
obtain a high surface-to-volume ratio which increases the activity of the 
nanoparticles and decrease the required dosage. Additionally, smaller nanoparticles 
are known for their enhanced cellular penetration with less cell membrane damage 
which is beneficial.118  
2- A simple synthetic method preferably in aqueous conditions is needed. The use of 
organic synthetic methods is costly and produces nanoparticles with toxicity 
concerns.113 The simplicity of the synthetic method will positively reflect on the 
reproducibility of the method, the potential for scale-up and the commercial 
translation. 
3- The colloidal stability of cerium oxide nanoparticles is often overlooked in the 
literature. This partly explains the discrepancies often found in the data reported. 
Therefore, it was of utmost importance to produce nanoparticles that stay suspended 
without aggregation or sedimentation in the physiological media intended for 
biological testing. Coating the nanoparticles is a common strategy for achieving good 
colloidal stability. 
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Ethylene glycol is known for its biocompatibility and hydrophilicity, and therefore its choice 
for aqueous coating of nanoceria was considered.113 However, in one study ethylene glycol 
was reported to produce nanoparticles with significant polydispersity and sedimentation. 
This clearly excludes it from being useful in biomedical applications.113 In the work carried 
out in this thesis, however, a novel strategy for the synthesis of the nanoparticles has made 
it possible to use ethylene glycol and produce monodisperse nanoparticles with an ultra-
small particle size (2-5 nm). This was conducted by simply changing the starting cerium 
precursor from a nitrate to an acetate. The acetate ligands introduced to the reaction partially 
modified ethylene glycol and produced a hybrid coat of ethylene glycol and mono- and di-
acetate derivatives endowing the nanoparticles (EGCNPs) with superior colloidal stability 
and monodispersity in various physiological media. One concern was that such coating may 
block the surface antioxidant activity of the nanoparticles, but it was demonstrated that they 
retain their activity in presence of such coating. The strategy described in this work can also 
be expanded to enhance the colloidal stability and monodispersity of other types of inorganic 
nanoparticles without adding to the complexity of the synthetic route.  
Fluorescent labelling of the nanoparticles was needed in order to use them for imaging 
studies. In the literature, it is common practice to label the surfaces of the nanoparticles with 
fluorescent probes such as FITC or rhodamine. However, this significantly changes the 
surface properties of the nanoparticles and poses the risk of changing their behaviour.116 In 
the work described in this thesis, this was addressed by doping the nanoparticles with 
europium which resulted in the formation of nanoparticles with similar surface properties. 
Even though doping with europium is not a novel strategy per se, the successful tracking of 
europium doped cerium oxide nanoparticles (EuCNPs) in any cell line is reported for the 
first in the work described in this thesis. It was feasible to obtain strong fluorescent emissions 
in the red region of the light spectrum where cellular autofluorescence is minimal. It should 
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be noted that the natural weak fluorescence of unlabelled pure nanoceria was also 
successfully detected in the cells for the first time utilising the ability of cerium oxide to 
resist photobleaching. This further validated europium doping not altering the localisation 
pattern of the nanoparticles.  
Having obtained cerium oxide nanoparticles with required particle size, monodispersity, 
colloidal stability, and fluorescent properties, the way was paved to employ them in 
biological testing. The first thing that needed to be investigated was to assess the formulation 
safety in HLECs. These are the stem cells of the lens where the majority of the metabolic 
activities takes place including crystallin synthesis and differentiation into fibre cells that 
make up the bulk of the lens body. The effect of the nanoparticles on several cellular 
parameters were assessed in a dose-dependent manner. These parameters included studying 
the effects of the nanoparticles on the mitochondrial morphology, mitochondrial membrane 
potential, ATP level, cell proliferation, cell membrane integrity and apoptosis. The results 
of these investigations showed that these nanoparticles were highly safe even when used at 
very high concentrations (≤200 µg/ml) with no signs of decreased proliferation or 
mitochondrial damage. This level of safety at such a high concentration is unprecedented 
where another nanoceria formulation showed genotoxic effect in HLECs at half this 
concentration (100 µg/ml).6 The reported safe concentrations of nanoceria tested on different 
cell lines were also much lower.6 It is possible that the superior colloidal stability is behind 
this jump in the tolerability of nanoparticles where sedimentation and aggregation are known 
causes of increased toxicity. The nanoparticles were also synthesised at a low temperature 
(40 °C) which is reported in the literature to produce less toxic and more antioxidative 
nanoparticles.216 This emphasises the need to test the colloidal stability of any new 
formulation before employing them in biological experiments. It is worthy of note that many 
other factors play a role in the toxicity profile including Ce4+/Ce3+ ratio, particle size, the 
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morphology, the purity, the starting precursor, the adsorption of protein coronae, the zeta 
potential, and the used cell line.143 Therefore, the safety level of a formulation always needs 
to be assessed on a case by case basis.  
No matter how safe a formulation is, an overdose risks generating toxic or undesirable effects. 
There was a lack of understanding about the mechanism of the cytotoxic and genotoxic 
effects of nanoceria when used at higher concentrations. In the work described in this thesis, 
the mechanism of nanoceria toxicity was investigated after 24-hour exposure in HLECs. At 
high nanoceria concentrations (400 µg/ml), intracellular levels of ROS were increased and 
the HLECs exhibited classical hallmarks of apoptosis. These findings concur with the cells 
maintaining normal ATP levels necessary to execute the apoptotic process. These results 
highlight the need for nanoceria dose-effect studies on a range of cells and tissues to identify 
therapeutic concentrations in-vitro or in-vivo.  
When the safe level of nanoceria was determined in HLECs, testing if they provide 
protective action against oxidative stress was set as the next objective. It could be argued 
that these nanoparticles are already known for their antioxidant properties, so they are 
guaranteed to protect against oxidative stress. However, this is not always the case where 
nanoceria tested in some cell lines were previously reported in the literature not to have any 
protective effects against oxidative stress.143 In other cell lines, nanoceria could not enter the 
cells and hence they could not protect the cells either.154 So testing the uptake, localisation 
and the actions of the nanoparticles needed to be assessed for EGCNPs in HLECs. The 
results described in this thesis show extensive uptake of EGCNPs. Importantly, most of these 
nanoparticles localised in the mitochondria which was very promising given that these are 
the organelles where the majority of ROS are generated. It was subsequently found through 
a series of studies, that such localisation leads to the protection of HLECs against induced 
oxidative stress and nanoparticles exerted in-vitro catalase mimetic action in cells with 
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inhibited catalases. The nanoparticles actions did not stop there as it was found that 
GSH/GSSG ratio increased dramatically in EGCNPs treated cells. This is a remarkable 
finding given the strong association between decreased GSH/GSSG ratio and cataract 
progression in nearly all cataract models.26 The work in this thesis was concluded by 
showing that EGCNPs not only provide antioxidative actions, but they can also provide 
protection against  the glycation of lens proteins. To the best knowledge of the author, this 
is the first single drug entity that has been demonstrated to collectively provide antioxidative, 
anti-glycating, GSH promoting and catalase mimetic effects in HLECs. Given the 
multifactorial nature of cataracts and the potential to add more functionalities to the 
nanoparticles, EGCNPs have great potential for cataract treatments and should be tested in-
vivo. 
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5.2 Recommendations for future work 
The research carried out in this thesis has opened new avenues for future work: 
1- EGCNPs should be tested in ex-vivo and in-vivo models to study if their protective 
actions can be replicated. These studies should include protection against glycation, 
oxidative stress and glutathione depletion. Ex-vivo studies on porcine lenses would be a 
suitable start because of the similarity of protein content compared to the human lenses. 
The ability of the nanoparticles to pass through the lens capsule into the lens epithelium 
needs to be assessed.  
2- The need for more representative in-vitro cellular models of the human lens epithelium 
is desirable. Culturing HLECs on three dimensional (3D) substrates should be 
investigated. 
3- It is not yet known by which mechanism EGCNPs protect against protein glycation and 
if it is the only PTM it protects against. Recent advances in mass spectrometry facilitate 
the identification and characterisation of various PTMs. This needs further work.  
4- An ideal formulation for cataract would have to be administered topically. Corneal 
permeability of EGCNPs need to be assessed and enhanced if needed. The encapsulation 
of EGCNPs in various kinds of polymeric or lipidic nanoparticles is a possible strategy 
if needed. Injection of a formulation into the aqueous humour is a possible strategy but 
not preferred as it will not be convenient for patients.  
5- Europium-doped nanoceria (EuCNPs) seem to have an extraordinary capability of 
targeting the mitochondria. TEM studies are required for precise determination of 
EGCNPs localisation in various organelles including the mitochondria. SEM-EDX is a 
convenient and quick tool. However, the purity of the mitochondrial fractions should be 
assessed before analysis by checking for marker enzymes. Given their characteristic 
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excitation/emission properties, low cost and ease of synthesis, EuCNPs have a great 
potential to act as mitochondrial probes replacing the less versatile and more expensive 
Mitotracker™ dyes. This needs optimisation and testing in various cell lines. The safety 
and antioxidant activity of the doped nanoparticles should also be studied.  
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Appendix 
1- Calculation of XRD crystallite size employing the Scherrer equation  
dXRD = 
0.94λ
FWHM cos 𝜃
 
where λ is the x-ray radiation wavelength (A°), θ is the Bragg diffraction angle for (111) 
plane, and FWHM is full width half maximum (in radians) of the diffraction peak at 
(111). 
dXRD = 
0.94 X 1.5
0.0427 cos 28.4
 = 34.6 A° = 3.46 nm 
 
2- ICP calibration curve (cerium) 
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3- Negative control of HLECs stained with Hoechst 33342 (blue) showing no 
EGCNPs green fluorescence at ex/em: 488/530 nm  
 
 
